

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Healthcare professionals knowledge, attitude and practice of reporting adverse drug reactions in Ethiopia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034553
Article Type:	Original research
Date Submitted by the Author:	26-Sep-2019
Complete List of Authors:	gidey, kidu; Mekelle University College of Health Sciences, clinical pharmacy; seifu, mohammedamin; Mekelle University, clinical pharmacy Hailu, Berhane; Mekelle University, Pharmacy Asgedom, Solomon Weldegebreal; School of Pharmacy, Mekelle University Niriayo, yirga; Mekelle University, clinical pharmacy
Keywords:	Adverse drug reaction, healthcare professionals, knowledge, practice

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Healthcare professionals knowledge, attitude and practice of reporting adverse drug reactions in Ethiopia

Kidu Gidey<sup>1\*</sup>, Mohammedamin Seifu<sup>1</sup>, Berhane Yohannes Hailu<sup>1</sup>, Solomon Weldegebreal Asgedom<sup>1</sup>, Yirga Legesse Niriayo<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

\*Corresponding author: Kidu Gidey; [kidupharm@gmail.com](mailto:kidupharm@gmail.com) (KG)

## Abstract

**Objective:** The aim of this study was to assess the knowledge, attitude, and practice of adverse drug reactions (ADRs) reporting and identify factors associated with reporting ADRs among healthcare professionals (HCPs) working in Tigray region, Ethiopia.

**Materials and Methods:** A cross-sectional study was conducted between January and March of 2019 in a tertiary care hospital in Tigray region, Ethiopia. A self-administered, pretested questionnaire was administered to HCPs. Data were analyzed using STATA version 14.1 (STATA Corp, TX, USA). Logistic regression analysis was used to identify factors associated with poor ADRs reporting practice.

**Results:** In total, 362 questionnaires were distributed, and the response rate was 84.8% (n = 307). Of all respondents, 190 (61.9%) were nurses, 63 (20.5%) were pharmacist, and 54 (17.6%) were physicians. About 58.3% of HCPs had poor knowledge of ADRs reporting. The majority of the respondents had a positive attitude (59.9%), and only a few (32.1%) respondents have good ADRs reporting practice. Poor knowledge (Adjusted odds ratio (AOR)= 2.63, 95% confidence interval (CI): 1.26- 5.45), lack of training on ADRs reporting (AOR= 7.31, 95% CI:

3.42- 15.62) and work experience ( $\geq 10$  years) (AOR= 0.36, 95% CI: 0.13- 0.97) were the predictors of poor ADRs reporting practice.

**Conclusions:** The majority of healthcare professionals had poor knowledge and practice, but a positive attitude toward reporting ADRs. Poor knowledge, less work experience and lack of training were predictors of poor ADRs reporting practice. Hence, strategies to improve the knowledge and practice of reporting ADRs should be implemented, particularly for untrained and less experienced HCPs.

**Keywords:** Adverse drug reaction, healthcare professionals, knowledge, practice

### Strengths and limitations of this study

The article provides interesting information related to pharmacovigilance in Ethiopia and will help policymakers understand the factors for underreporting of ADRs in Ethiopia.

The cross-sectional design of this study may not establish a causal relationship between ADRs reporting and explanatory variables

Our study was conducted in a single centre.

### Introduction

Adverse drug reactions (ADRs) are a major cause of morbidity and mortality and contribute to the occurrence of adverse events, leading to increased healthcare costs [1]. ADRs account for up to 6.5% of all hospitalizations [2]. Information on ADRs can be obtained from preclinical studies and clinical studies, but rare adverse reactions that occur only in a few cases after prolonged use of drugs or after interactions with other established drugs may not be detected during this period [3].

Therefore, a thorough study of post-marketing adverse drug reactions is essential to patient safety

1  
2  
3 [4]. Once a drug is registered and marketed, adverse reaction studies can be conducted using a  
4 variety of methods, such as observational studies, monitoring of prescription events, spontaneous  
5 reports and so on [5]. However, the health care system relies heavily on the spontaneous reporting  
6 of ADRs to monitor drug safety throughout the population during actual use [6].  
7  
8  
9  
10  
11  
12

13  
14 Although different studies have documented that new adverse reactions are effectively discovered  
15 through spontaneous reporting compared to other methods, poor reporting practice is a major  
16 limitation of spontaneous reporting systems [7]. Low rates of adverse reaction reporting are a  
17 major health concern and may delay regulatory actions to remove drugs with an unacceptable  
18 safety profile from the marketplace [8]. Healthcare professionals are responsible for identifying,  
19 documenting and reporting ADRs. Their contribution to the early detection and reporting of ADR  
20 is essential [9]. However, ADR reporting is affected by many factors, including lack of awareness,  
21 ambiguity about who should report, difficulties with reporting procedures, lack of feedback on  
22 submitted reports, rapid resolution of adverse events, and so on [10, 11]. The knowledge and  
23 attitudes of health professionals are strongly related to ADRs reporting [12, 13]. Therefore, it is  
24 very important to understand the knowledge and practice of health care providers related to ADR  
25 reporting to improve reporting practices [14].  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Although local regulatory authorities can make drug safety decisions using ADR data from other  
45 countries, it is essential to take into account a number of factors, such as local population traditions,  
46 genetics, diet, environmental factors, etc [15]. Therefore, it is very important to establish a local  
47 functional ADR monitoring center. Ethiopia established its own pharmacovigilance system under  
48 the Food and Drug Administration and control authority in 2002. Since the introduction of the  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 pharmacovigilance system, the number of adverse reactions reported to the center is limited [16].  
4  
5 In addition, studies on identifying factors and reasons for poor reporting practices are limited in  
6  
7 our context. The aim of this study was therefore to determine the knowledge, attitudes and  
8  
9 practices of reporting ADRs and to identify predictive factors for poor ADR reporting practices  
10  
11 among health professionals in a tertiary hospital in the Tigray region, Ethiopia.  
12  
13  
14

## 15 **Materials and Methods**

### 16 **Study setting and period**

17  
18  
19 The study was conducted at Ayder comprehensive specialized hospital (ACSH), Tigray region,  
20  
21 Northern Ethiopia. ACSH is a teaching and referral hospital with 500 beds. The hospital serves for  
22  
23 more than 9 million people in the catchment area. ACSH provides all the specialized and non-  
24  
25 specialized hospital services including emergency services, outpatient services and inpatient  
26  
27 services. Healthcare professionals working in all of these areas were included in this study between  
28  
29 January and March of 2019.  
30  
31  
32  
33  
34

### 35 **Study design and population**

36  
37  
38 An institutional based cross-sectional study was conducted. The target populations for this  
39  
40 study were nurses, physicians and pharmacists working in ACSH during the study periods.  
41  
42 Healthcare professionals who were refused or did not wish to participate in the study were  
43  
44 excluded.  
45  
46

### 47 **Sample Size Determination and sampling technique**

48  
49 The sample size was calculated using a single proportion sample size estimating formula

$$50$$
$$51$$
$$52$$
$$53 \quad n = \frac{(z_{1-\alpha/2})^2 P(1-P)}{d^2} = \frac{(1.96)^2 0.66(1-0.66)}{0.05^2} = 344.8 \approx 345$$
$$54$$
$$55$$
$$56$$
$$57$$
$$58$$
$$59$$
$$60$$

1  
2  
3 Where,  $n$  = sample size,  $Z$  = confidence interval (1.96)  $p$  = The proportion of health care  
4 professionals with poor knowledge of ADR reporting (65.8,  $p= 0.66$ ), obtained from a study  
5 conducted in Amhara region of Ethiopia [17], and  $d$  = Margin of error to be tolerated (0.05).  
6  
7  
8  
9  
10 By adding 5% ( $345 \times 0.05 = 17$ ) of the sample size to compensate non-respondents, the total  
11 sample size required was 362. Subjects were recruited using stratified random sampling  
12  
13  
14  
15 technique according to their profession.

## 16 17 **Outcome measures**

18  
19 In this survey, knowledge of ADRs reporting was assessed using nine questions containing  
20 general knowledge about ADR and ADR reporting. Each correct answer had a score of 1 and  
21 each wrong answer had a score of 0. Thus, the total score ranged from 0 to 9 points. The  
22 overall level of knowledge was categorized using the mean score. Participants with above  
23 mean scores were classified as having good knowledge and below mean scores were  
24 classified as poor knowledge. Participants' attitudes were assessed using ten items rated as  
25 agreeing, neutral, and disagreeing on a three-point Likert scale. The "agree" responses  
26 received a score of 3, "neutral" a score of 2, and "disagree" a score of 1. An inverted score  
27 was made for the negative-worded questions. Therefore, the maximum possible attitude score  
28 was 30. The mean attitude score was calculated for each respondent on the basis of which  
29 their attitude was categorized as positive and negative. The level of practice of health  
30 professionals was assessed by determining whether they had encountered, documented and  
31 reported ADRs or not. Participants were classified as having good practice if they had  
32 reported one or more ADRs and poor practices, if they had never reported ADR, despite  
33 encountering ADRs.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **Data collection**



1  
2  
3 The Data Collection Tool is a questionnaire that was adopted from similar previous studies on the  
4 knowledge, attitudes, and practices of health care professionals on ADR reporting [18-20]. A pre-  
5 test was performed to validate the questionnaire and minor modifications were made accordingly  
6  
7  
8 The prepared self-administered questionnaire contained four different sections. The first section  
9  
10 contained demographic information. The second section consists of nine questions used to measure  
11  
12 the knowledge of HCPs related to ADR reporting. The third section consisted of ten questions,  
13  
14 which assessed participants' attitudes toward ADR reporting. The fourth section is about the  
15  
16 practice of ADR reporting..  
17  
18  
19  
20

## 21 **Statistical methods**

22  
23  
24 The data were coded, double-entered into Epi data management (version 4.2.0) and statistical  
25 analysis was performed using STATA version 14.1 (STATA Corp, TX, USA). Descriptive  
26 analysis was computed using mean (SD) for quantitative variables and frequency for categorical  
27 variables. To determine the factors associated with ADR reporting, univariate and multivariate  
28 logistic regression tests were used. The dependent variable was ADR reporting, while  
29 demographics, knowledge and attitude were included as the independent variables. Values were  
30 considered as significant at p-value of  $<0.05$  ( $\alpha=0.05$ ).  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 **Ethical considerations**

41  
42  
43 The ethical approval and clearance were obtained from Ethics Review Committee of the School  
44 of Pharmacy, College of Health Sciences, Mekelle University (reference number:  
45 CHS/161/pharm-11). In addition, a brief description of the objective of the study was provided  
46 for all the participants to avoid ambiguity and misunderstanding. The data collection process was  
47 initiated after the willingness of the health professionals was requested and formal written consent  
48 was obtained.  
49  
50  
51  
52  
53  
54  
55  
56

## Patient and Public Involvement

No patient involved

## Results

### Demographic characteristics

In the current study, 362 questionnaires were distributed. Of these, 307 were duly completed and returned, giving a response rate of 84.8%. Of all respondents, 190 (61.9%) were nurses, 63 (20.5%) were pharmacist, and 54 (17.6%) were physicians. About 50% of respondents have less than five years of experience and more than half of the participants had not received any training on adverse drug reactions (table 1).

Table 1: Socio-demographic characteristics of respondents at ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Variable	Frequency (%)
Sex	
Male	156 (50.8)
Female	151 (49.2)
Age	
<25	63(20.5)
25-34	199(64.8)
≥35	45(14.7)
Profession	
Physician	54 (17.6)
Pharmacy	63 (20.5)
Nurse	190 (61.9)
Work experience (years)	
< 5	156 (50.9)

5-9	121 (40)
≥10	28 (9.1)
Trained on ADR reporting	
Yes	138(44.95)
No	169(55.05)

## Knowledge of adverse drug reaction reporting

There were nine questions assessing knowledge of adverse drug reactions. Only 29.3% of respondents knew the exact definition of adverse reactions and 36.8% of respondents knew what to report. A small proportion of respondents (19.5%) were aware of the classification of adverse drug reactions. Of the respondents, 39.4% of the respondents felt they were aware of the availability of the National Reporting Center in Ethiopia and a small proportion of the respondents (31.9%) knew where to report. The mean score  $\pm$  SD of the level of knowledge of ADRs among health professionals was  $4.17 \pm 2.07$  out of a maximum of 9 points. Overall, the majority (58.3%) of health professionals had poor knowledge of ADR reporting (table 2).

Table 2: knowledge of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Variables	Frequency (%)
Which of the following defines ADR correctly?	
Any noxious or undesired effect of drug occurring at normal dose, during normal use*	90 (29.3)
Adverse health outcomes associated with inappropriate drug use	51 (16.6)
Harm resulting from the use of substandard/counterfeit drugs	26 (8.5)
Harm caused by drug overdose	67 (21.8)
All can define ADR	73 (23.8)
Which ADR should be reported?	
All series ADRs	113 (36.8)
ADRs to herbal and non-allopathic drugs	15 (4.9)
ADRs to new drugs	49 (16.0)
ADRs to vaccines drugs	8 (2.6)
Unknown ADRs to old drugs	9 (2.9)

1		
2		
3	All of the above*	113 (36.8)
4	The correct classification of the type of ADR	
5	Type A,B,C,D,E,and F*	60 (19.5)
6	Type 1,2,3,4,5,6 and 7	62 (20.2)
7	Known, unknown and common, uncommon	89 (29.0)
8	Reversible and irreversible	64 (20.8)
9	Do not know	31 (10.1)
10		
11	Is there any center /ADR reporting system in Ethiopia	
12	Yes	121 (39.4)
13	No	141 (45.9)
14	Don't know	45 (14.7)
15		
16	All ADRs are known before a medicine is marketed	
17	Yes	99 (32.2)
18	No*	168 (54.7)
19	Don't know	40 (13.0)
20		
21	Are you aware of any drug that banned due to ADR	
22	Yes*	98 (31.9)
23	No	176 (57.3)
24	Don't know	33 (10.7)
25		
26	Where it reported in Ethiopia	
27	Manufacturers	17 (5.5)
28	Ministry of health of Ethiopia	68 (22.1)
29	Ethiopian pharmaceutical association	47 (15.3)
30	DTC of respective health facility	49 (16.0)
31	FMHACA*	98 (31.9)
32	Pharmacy dept	28 (9.1)
33		
34	Do you think that ADR is the same with side effect?	
35	Yes	127(41.4)
36	No*	180(58.6)
37		
38	Which of the following is the major risk factor for the occurrence of	
39	maximum adverse drug reactions	
40	Arthritis	30 (9.8)
41	Renal failure*	147 (47.9)
42	Visual impairment	24 (7.8)
43	All of these	106 (34.5)
44		
45	Overall knowledge score	
46	Good	128 (41.7)
47	Poor	179 (58.3)

ADR: adverse drug reaction, DTC: drug and therapeutic committee STG: standard treatment guideline DACA: Drug Administration and Control Authority, FMHACA: Food, Medicine and Healthcare Administration and Control Authority, \*correct answers

## Attitude of health professionals toward ADR reporting

Regarding healthcare professionals' attitudes to reporting adverse drug reactions, the majority (67.4%) of respondents agreed that it is necessary to report, while 37.8% agreed that reporting adverse drug reactions should be mandatory. Most respondents (51.1%) disagreed with the idea that only prescribed medication should be reported. Overall, about 60% of respondents showed a positive attitude towards reporting ADRs (table 3).

Table 3: Attitude of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Responses		
	Agree, n (%)	Neutral n (%)	Disagree n (%)
ADR reporting is necessary	207 (67.4)	23 (7.5)	77 (25.1)
Reporting ADR should be mandatory for all HCPs	116 (37.8)	62 (20.2)	129 (42.0)
ADR reporting increase patient's safety	148 (48.2)	66 (21.5)	93 (30.3)
Reporting ADR is important for health care system	135 (44.0)	73 (23.8)	99 (32.2)
There is a need to be sure that ADRs are related to the drug before reporting	194 (63.2)	35 (11.4)	78 (25.4)
Only ADR of prescription drug needs to be reported	82 (26.7)	68 (22.1)	157 (51.1)
One report of ADR makes no differences	103 (33.6)	78 (25.4)	126 (41.0)
The yellow card is difficult to fill up	177 (57.7)	88 (28.7)	42 (13.7)
Reporting creates additional workload and it is time consuming	199 (64.8)	78 (25.4)	30 (9.8)
Establishing ADR reporting center in every hospital is important	189 (61.6)	44 (14.3)	74 (24.1)
Overall level of attitude			
Positive	184 (59.9%)		
Negative	123 (40.1%)		

## Practices of health professionals about ADR reporting

Of the 307 health professionals, 74.9% encountered ADR in last 12 month of their clinical practice, and 29.1% of them recorded in patient card. Although most health care professionals experienced ADR, only 32.1% reported it (table 4).

Table 4: Practice of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Category	Frequency (%)	
Have you ever encountered patient with ADR in your clinical practice in the last 12 months	Yes	230(74.9)	
	No	77 (25.1)	
How many patients with ADR have you encountered during the last 12 months?	None	77 (25.1)	
	One	13 (4.2)	
	Two	58 (18.9)	
	Three	61 (19.9)	
	Four	52 (16.9)	
Have you noted the ADR you encountered on the patient clinical record (n=230)	More than four	46 (15.0)	
	Yes	67 (29.1)	
	No	163 (70.9)	
	How often do you give advice to your patients on possible ADRs you prescribed, dispensed or administered	Usually	118 (38.4)
		Never	89 (29.0)
Sometimes		69 (22.5)	
Always		31 (10.1)	
If you encountered ADR, have you ever reported the ADR? (n=230)	Yes (good practice)	74 (32.1)	
	No (poor practice)	156 (67.9)	

## Factors associated with poor ADR reporting practice

A univariable logistic regression analysis was performed to determine the association of each variable with the practice of ADR reporting. In the univariable analysis work experience of the HCPs ( $\geq 10$  years) (crude odds ratio (COR)= 0.31, 95% CI: 0.15- 0.64), negative attitude ( COR= 2.08, 95% CI: 1.17-3.72), poor knowledge (COR= 3.49, 95% CI: 1.95- 6.23), lack of training on

ADR reporting (COR= 7.67, 95% CI: 4.07- 14.46), and nursing profession (COR= 2.11, 95% CI: 1.06- 4.20), were associated with poor ADR reporting practice. Subsequent multivariable logistic regression model was conducted to identify the independent predictors. The full model containing all predictors was statistically significant ( $X^2 = 69.78$ ,  $df = 10$ ,  $P$ -value < 0.001). The results of the multivariate logistic regression indicated that only work experience of the HCPs ( $\geq 10$  years) (AOR= 0.36, 95% CI: 0.13- 0.97), poor knowledge (AOR= 2.63, 95% CI: 1.26- 5.45), and lack of training on ADR reporting (AOR= 7.31, 95% CI: 3.42- 15.62) were the predictors of poor ADR reporting practice (table 5).

Table 5: Univariable and multivariable logistic regression analysis of associated factors of poor ADR reporting practice in Tigray Region, Ethiopia from January 2019 to March 2019 (n=230)

Variable	ADR reporting practice		P value	COR (95% CI)	AOR (95% CI)	P value
	Yes, n (%)	No, n (%)				
<b>Gender</b>						
Male	44 (59.5)	73 (46.8)		1	1	
Female	30 (40.5)	83 (53.2)	0.07	1.67(0.95, 2.92)	1.51(0.77, 2.94)	0.23
<b>Age (years)</b>						
<25	15(20.3)	29(18.6)		1		
25-34	48(64.9)	100(64.1)	0.84	1.09(0.53, 2.19)	1.22(0.46, 3.23)	0.68
$\geq 35$	11(14.9)	27(17.3)	0.62	1.27(0.49, 3.24)	3.40(0.93, 12.48)	0.07
<b>Experience (years)</b>						
< 5	27(36.5)	84(53.8)		1	1	
5-9	24(32.4)	50(32.1)	0.23	0.67(0.35, 1.28)	1.42(0.57, 3.52)	0.45
$\geq 10$	23(31.1)	22(14.1)	0.001	0.31(0.15, 0.64)	0.36(0.13, 0.97)	0.04
<b>Profession</b>						
Pharmacist	20(27.0)	26(16.7)		1	1	
Physician	16(21.6)	26(16.7)	0.61	1.25(0.53, 2.93)	2.15(0.70, 6.56)	0.18
Nurse	38(51.4)	104(66.7)	0.04	2.11(1.06, 4.20)	1.36(0.57, 3.26)	0.49

Attitude							
Positive	50(67.6)	78(50)		1			
Negative	24(32.4)	78(50)	0.01	2.08 (1.17, 3.72)	1.24(0.59, 2.59)		0.57
Knowledge							
Good	48(64.9)	54(34.6)		1			
Poor	26(35.1)	102 (65.4)	<0.001	3.49(1.95, 6.23)	2.63(1.26, 5.45)		0.01
Training provided							
Yes	56(75.7)	45(28.8)		1			
No	18(24.3)	111(71.2)	<001	7.67(4.07, 14.46)	7.31(3.42, 15.62)		<0.001

ADR: adverse drug reaction, AOR: adjusted odds ratio, COR: crude odds ratio

## Discussion

One of the main goals of this study was to investigate the knowledge of HCPs towards ADRs and its reporting. This issue is critical for research to identify the necessary interventions, as HCPS cannot effectively participate in the reporting without sufficient knowledge of the ADR and its reporting process. We found that only 41.7 % of HCPs had good knowledge about ADR reporting, similar to the reports seen in Amhara region of Ethiopia (47%) [21], West Ethiopia (48 %) [22], Saudi Arabia (39.6%) [23], and Nepal (39.4%) [24]. These findings suggest that the knowledge of HCPs on ADRs reporting is insufficient. However, this result was lower compared to previous findings reported in Philippines (77%) [25] and in Kuwait (61.5%) [26]. This discrepancy may be due to differences in government involvement in national pharmacovigilance programs, study participants, and training level. The current study was conducted in a system where national ADR reporting methods were in its infancy and most HCPs (55%) did not receive any ADR reporting training.



1  
2  
3 Our study showed that 39.4% of HCPs were aware of the existence of an ADR system in Ethiopia.  
4  
5 This meant that most of the participants did not have information about the authority responsible  
6  
7 for monitoring ADR in Ethiopia. This is similar to the study conducted in Addis Ababa, Saudi  
8  
9 Arabia, and Jordan, which reported lack of knowledge about the national ADR reporting system  
10  
11 [27-29]. This is a critical observation, which is undoubtedly related to the current underreporting  
12  
13 of ADRs. In addition, only 31.9 % of the HCPs know where to report ADR. This could be as a  
14  
15 result of limited awareness and support for ADR monitoring.  
16  
17  
18  
19

20 Regarding the level of attitude, we found that about 60 % of HCPs had a positive attitude on ADR  
21  
22 and its reporting. Although majority of the respondents have positive attitude, the result is lower  
23  
24 compared to previous findings in Amhara region of Ethiopia (86%) [21] and India (90%) [29].  
25  
26 Most respondents (67.4%) felt that reporting adverse reactions is necessary, which is consistent  
27  
28 with previous studies [20, 21]. However, 64.8% of the respondents agreed that reporting creates  
29  
30 an additional workload, which is higher than the results obtained in the Amhara region (32.4%)  
31  
32 [21]. Although it may take some time to complete the report forms, the high proportion of  
33  
34 respondents with such perception found in our study may affect the motivation to report adverse  
35  
36 reactions.  
37  
38  
39  
40

41 Another important finding was that ADRs reporting practices among HCPs were very poor.  
42  
43 Although more than 75% of respondents encountered one or more ADRs in their daily practice,  
44  
45 only 32.1% of respondents reported ADRs. This is consistent with a study conducted in Amhara  
46  
47 Region of Ethiopia and south India [30, 31]. The study also identified predictors of poor ADR  
48  
49 reporting practice. Less experienced HCPs were more likely to have poor ADR reporting practices.  
50  
51 This finding is consistent with a study conducted in Uganda, where more experienced HCPs were  
52  
53 four times more likely to have ever reported than less experienced professionals [31]. Health  
54  
55  
56  
57

1  
2  
3 professionals with poor knowledge were more likely to have a poor practice of reporting ADRs.  
4  
5 The association of poor knowledge levels of health professionals with poor ADR reporting practice  
6  
7 has been observed in many similar previous studies [31-35]. Moreover, health professionals who  
8  
9 had not received ADRs reporting training were more likely to have poor practice. This is also  
10  
11 supported by a study carried out in Spain [36]. However, only 44.95% of the respondents were  
12  
13 trained in our study. Similarly, HCPs have shown limited training in areas of ADR and their  
14  
15 reporting in studies conducted in Sudan [33] and Uganda [31]. Thus, more training regarding the  
16  
17 identification of ADR, the purpose of the ADR reporting, and the availability of resources for ADR  
18  
19 reporting is required.  
20  
21  
22

23  
24 These findings have important implications. The low level of knowledge of the adverse drug  
25  
26 reaction and its reporting among HCPs should be enhanced by designing different strategies.  
27  
28 Different studies have shown improved knowledge and attitude scores after educational  
29  
30 interventions related to pharmacovigilance and ADR reporting's [37-40]. Therefore, empowering  
31  
32 HCPs in detecting and reporting suspected drug reactions is essential to strengthening  
33  
34 pharmacovigilance systems in Ethiopia. This is especially important for less experienced health  
35  
36 professionals and for those who had never received training on ADR reporting. However,  
37  
38 additional research needs to be done to investigate the impact of this intervention on the knowledge  
39  
40 and practice of ADR reporting in our setting.  
41  
42  
43  
44

45  
46  
47 Finally, there are several limitations to this study. We used a self-report as the main method of  
48  
49 inquiry, which may have introduced recall bias. The HCPs may have made explicit responses to  
50  
51 the fear that they would be embarrassed if they did not report ADRs. However, because we used  
52  
53 self-administered questionnaires without respondents' names, the potential for this bias was  
54  
55  
56  
57

1  
2  
3 reduced. The cross-sectional design we used may not establish a causal relationship between ADR  
4 reporting and explanatory variables. Finally, the study was conducted in a tertiary referral hospital  
5 and may not be generalized for all HCPs in different health care level in the country. Despite these  
6 limitations, our study has generated important insights on knowledge, attitude, and practice of  
7 ADR reporting and predictors of poor ADRs reporting practice.  
8  
9  
10  
11  
12  
13

## 14 **Conclusion**

15  
16  
17 **The majority of health professionals had poor knowledge and practice, but a positive attitude**  
18 **toward reporting ADRs.** Poor knowledge, less work experience and lack of training were  
19 predictors of poor ADR reporting practice. Therefore, strategies to improve knowledge and  
20 practices regarding ADR reporting should be implemented. Training should be provided to all  
21 HCPs, especially those who have never received training and less experienced professionals.  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **Acknowledgments**

31  
32  
33 The authors would like to thank the College of Health Science, Mekelle University for their  
34 support and cooperation. The authors would also like to thank for all Ayder comprehensive  
35 specialized hospital staff members for their willingness to participate and dedicate their valuable  
36 time to fill the questionnaire  
37  
38  
39  
40  
41  
42  
43

44 **Contributors:** KG and MS conceived the study and drafted the manuscript and contributed to  
45 data entry, data analysis, draft manuscript and final proof reading. BYH, SWA and YLN  
46 participated in study design, data analysis and in the process of manuscript writing. All authors  
47 approved the final manuscript.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Data Availability

The dataset of this study is available from the corresponding author upon request.

## Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

## Conflicts of Interest

The authors have declared that there is no conflict of interests with respect to the authorship and/or publication of this study.

**Participant consent:** Obtained.

## References

1. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. *Drug safety*. 2015;38(5):437-53.
2. Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, et al. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrenees region (PharmacomIP) network 2-year pilot study. *Drug safety*. 2010;33(5):409-16.
3. McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, et al. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. *Drug safety*. 2010;33(9):775-88.
4. Bandekar MS, Anwikar SR, Kshirsagar NA. Quality check of spontaneous adverse drug reaction reporting forms of different countries. *Pharmacoepidemiology and drug safety*. 2010;19(11):1181-5.
5. Huang Y-L, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. *Drug safety*. 2014;37(8):581-96.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
6. Sabblah GT, Akweongo P, Darko D, Dodoo ANO, Sulley AM. Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana. *Ghana Med J.* 2014;48(4):189-93.
7. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. *Drug safety.* 2006;29(5):385-96.
8. Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. *International journal of clinical pharmacy.* 2018;40(4):878-89.
9. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. *Ther Clin Risk Manag.* 2005;1(3):181-8.
10. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. *British journal of clinical pharmacology.* 2017;83(4):875-83.
11. Perez Garcia M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. *Pharmacoepidemiology and drug safety.* 2011;20(12):1295-302.
12. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. *Drug safety.* 2009;32(1):19-31.
13. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. *Drug safety.* 2013;36(5):317-28.
14. Alshammari TM, Alamri KK, Ghawa YA, Alohal NF, Abualkol SA, Aljadhey HS. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. *International journal of clinical pharmacy.* 2015;37(6):1104-10.
15. Alshami MAAAM, Azm MIMIM. The need of pharmacovigilance activities in Yemen. *Global Journal of Medical Research.* 2014.
16. Mulatu WN, Worku A. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. *Journal of Pharmacovigilance.* 2014.

17. Necho Mulatu W. Assessment of Knowledge, Attitude and Practice of Health Professionals towards Adverse Drug Reaction Reporting and Factors Associated with Reporting 2014.
18. Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. *Saudi Pharm J.* 2018;26(4):453-61.
19. Guner MD, Ekmekci PE. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. *Journal of drug assessment.* 2019;8(1):13-20.
20. Shanko H, Abdela J. Knowledge, Attitudes, and Practices of Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study. *Hospital pharmacy.* 2018;53(3):177-87.
21. Seid MA, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals' knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. *International journal of clinical pharmacy.* 2018;40(4):895-902.
22. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. *BioMed research international.* 2016;2016.
23. Abdel-Latif MM, Abdel-Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. *Saudi pharmaceutical journal.* 2015;23(2):154-61.
24. Palaian S, Ibrahim MI, Mishra P. Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. *Pharmacy practice.* 2011;9(4):228.
25. Carandang RR, Cao K, Jose NB, Almonte FD, Tinio RM. Research article knowledge and attitudes on adverse drug reaction reporting of selected hospital-based health practitioners in Manila, Philippines. *Sch Acad J Pharm (SAJP).* 2015;4:301-7.
26. Alsaleh FM, Alzaid SW, Abahussain EA, Bayoud T, Lemay J. Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. *Saudi Pharm J.* 2017;25(6):830-7.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
27. Goshime A. Assessment of Knowledge, Attitude and Practices on Adverse Drug Reaction Reporting among Pharmacy Personnel Working at Community Pharmacy, Addis Ababa, Ethiopia: Addis Ababa University; 2015.
28. Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, et al. Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. *Saudi pharmaceutical journal*. 2014;22(5):411-8.
29. Katekhaye VM, Kadhe NG, John J, Pawar SR. Knowledge, attitude and practice of pharmacovigilance among medical professionals at a tertiary care hospital in Mumbai, Maharashtra, India. *Int J Res Med Sci*. 2016;5:156-61.
30. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. *Perspectives in clinical research*. 2015;6(1):45.
31. Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. *Afr Health Sci*. 2015;15(4):1308-17.
32. Ohaju-Obodo J, Iribhogbe O. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. *Pharmacoepidemiology and drug safety*. 2010;19(2):191-5.
33. Elnour AA, Ahmed AD, Yousif MAE, Shehab A. Awareness and reporting of adverse drug reactions among health care professionals in Sudan. *The Joint Commission Journal on Quality and Patient Safety*. 2009;35(6):324-AP2.
34. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. *Drug safety*. 2006;29(5):385-96.
35. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. *British journal of clinical pharmacology*. 2001;51(1):81-6.
36. Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernandez-Diaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. *Drug safety*. 2007;30(11):1073-82.
37. Jha N, Rathore DS, Shankar PR, Bhandary S, Pandit RB, Gyawali S, et al. Effect of an educational intervention on knowledge and attitude regarding pharmacovigilance and

- 1  
2  
3 consumer pharmacovigilance among community pharmacists in Lalitpur district, Nepal.  
4 BMC research notes. 2017;10(1):4.  
5  
6  
7 38. Bisht M, Singh S, Dhasmana D. Effect of educational intervention on adverse drug  
8 reporting by physicians: a cross-sectional study. ISRN pharmacology. 2014;2014.  
9  
10 39. Li Q, Zhang S-M, Chen H-T, Fang S-p, Yu X, Liu D, et al. Awareness and attitudes of  
11 healthcare professionals in Wuhan, China to the reporting of adverse drug reactions.  
12 Chinese medical journal. 2004;117(6):856-61.  
13  
14  
15 40. Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge  
16 attitude practice of pharmacovigilance among health care professionals in an Indian tertiary  
17 care teaching hospital. Int J Pharm Tech Res. 2011;3(2):678-92.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	4 and 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	--
		(c) Explain how missing data were addressed	--
		(d) If applicable, describe analytical methods taking account of sampling strategy	--
		(e) Describe any sensitivity analyses	--
<b>Results</b>			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	---
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	--
Outcome data	15*	Report numbers of outcome events or summary measures	7-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	---
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	---
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13 and 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034553.R1
Article Type:	Original research
Date Submitted by the Author:	14-Nov-2019
Complete List of Authors:	gidey, kidu; Mekelle University College of Health Sciences, clinical pharmacy; seifu, mohammedamin; Mekelle University, clinical pharmacy Hailu, Berhane; Mekelle University, Pharmacy Asgedom, Solomon Weldegebreal; School of Pharmacy, Mekelle University Niriayo, yirga; Mekelle University, clinical pharmacy
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Health services research, Medical education and training, Pharmacology and therapeutics
Keywords:	Adverse drug reaction, healthcare professionals, knowledge, practice

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study

Kidu Gidey<sup>1\*</sup>, Mohammedamin Seifu<sup>1</sup>, Berhane Yohannes Hailu<sup>1</sup>, Solomon Weldegebreal Asgedom<sup>1</sup>, Yirga Legesse Niriayo<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

\*Corresponding author: Kidu Gidey; [kidupharm@gmail.com](mailto:kidupharm@gmail.com) (KG)

## Abstract

**Objective:** This study aimed to assess the knowledge, attitude, and practice of adverse drug reactions (ADRs) reporting and identify factors associated with ADRs reporting among healthcare professionals (HCPs) working in Tigray region, Ethiopia.

**Materials and Methods:** A cross-sectional study was conducted between January and March of 2019 in a tertiary care hospital in Tigray region, Ethiopia. A self-administered, pretested questionnaire was administered to HCPs. Data were summarized using descriptive statistics. Logistic regression analysis was used to identify factors associated with poor ADRs reporting practices.

**Results:** In total, 362 questionnaires were distributed, and the response rate was 84.8% (n = 307). Of all respondents, 190 (61.9%) were nurses, 63 (20.5%) were pharmacist, and 54 (17.6%) were physicians. About 58.3% of HCPs had poor knowledge of ADRs reporting. The majority of the respondents had a positive attitude (59.9%), and only a few (32.1%) respondents have good ADRs reporting practices. Poor knowledge (Adjusted odds ratio (AOR)= 2.63, 95% confidence interval (CI): 1.26- 5.45), and lack of training on ADRs reporting (AOR= 7.31, 95%

1  
2  
3 CI: 3.42- 15.62) were both negatively associated with ADRs reporting practice, whereas higher  
4  
5 work experience ( $\geq 10$  years) (AOR= 0.36, 95% CI: 0.13- 0.97) were positively associated with  
6  
7 ADRs reporting practice.  
8  
9

10 **Conclusions:** The majority of healthcare professionals had poor knowledge and practice, but a  
11  
12 positive attitude toward ADRs reporting. Poor knowledge, less work experience and lack of  
13  
14 training were associated with poor ADRs reporting practice. Hence, strategies to improve the  
15  
16 knowledge and practice of ADRs reporting should be implemented, particularly for untrained and  
17  
18 less experienced HCPs.  
19  
20

21  
22 **Keywords:** Adverse drug reaction, healthcare professionals, knowledge, practice  
23  
24  
25

## 26 **Strengths and limitations of this study**

27  
28 The article provides interesting information related to pharmacovigilance in Ethiopia and will  
29  
30 help policymakers understand the factors for ADRs underreporting in Ethiopia.  
31  
32

33 The cross-sectional design of this study may not establish a causal relationship between ADRs  
34  
35 reporting and explanatory variables  
36  
37

38 Our study was conducted in a single centre.  
39  
40

## 41 **Introduction**

42  
43  
44 Adverse drug reactions (ADRs) are a major cause of morbidity and mortality and contribute to the  
45  
46 occurrence of adverse events, leading to increased healthcare costs [1]. ADRs have become a major  
47  
48 public health problem in developing countries [2]. The median prevalence (with interquartile range  
49  
50 [IQR]) of ADR-related hospitalization in developing countries was 5.5% (1.1-16.9) [3]. The  
51  
52 information collected during the pre-marketing phase of drug development is inevitably  
53  
54  
55  
56  
57

1  
2  
3 incomplete concerning possible ADRs. This is due to the participation of a limited and selected  
4 number of patients who are studied before marketing, the conditions of drug use in clinical trials  
5 are different from those of clinical practice, the duration of the clinical trials is short, and high-  
6 risk patients (such as elderly patients) are often excluded [4]. Therefore, post-marketing  
7 surveillance is important to allow detection of less common, but sometimes very serious ADRs.  
8  
9  
10  
11  
12  
13  
14  
15 Once a drug is registered and marketed, adverse reaction studies can be conducted using a variety  
16 of methods, such as observational studies, monitoring of prescription events, spontaneous reports  
17 and so on [5]. However, the health care system relies heavily on spontaneous ADRs reporting to  
18 monitor drug safety throughout the population during actual use [6].  
19  
20  
21  
22  
23  
24  
25

26  
27 A spontaneous reporting system of ADRs is fundamental to effectively discover new adverse  
28 reactions but under-reporting is its major limitations [7, 8]. A systematic review of studies  
29 conducted in the European Union showed a significant and widespread healthcare professionals  
30 under-reporting of ADRs with a median rate of under-reporting of 94% [7]. The low rates of ADRs  
31 reporting may delay regulatory actions to remove drugs with an unacceptable safety profile from  
32 the marketplace. A worldwide systematic review of 462 medicines removed from the market for  
33 safety reasons showed that the median interval between the first reported adverse reaction and the  
34 year of first withdrawal was 6 years (IQR, 1-15) and the interval did not consistently shorten over  
35 time [9].  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46  
47 Healthcare professionals (HCPs) are responsible for identifying, documenting and ADRs  
48 reporting. Their contribution to the early detection and reporting of ADR is essential [10].  
49  
50  
51  
52 However, ADR reporting is affected by many factors, including lack of awareness, ambiguity  
53 about who should report, difficulties with reporting procedures, lack of feedback on submitted  
54  
55  
56  
57

1  
2  
3 reports, rapid resolution of adverse events, and so on [11, 12]. The knowledge and attitudes of  
4 health professionals are strongly related to ADRs reporting [8, 13]. Therefore, it is very important  
5 to understand the knowledge and practice of health care providers related to ADR reporting to  
6 improve reporting practices [14].  
7  
8  
9  
10  
11  
12

13  
14 Although local regulatory authorities can make drug safety decisions using ADR data from other  
15 countries, it is essential to take into account a number of factors, such as local population traditions,  
16 genetics, diet, environmental factors, etc [15]. Therefore, it is very important to establish a local  
17 functional ADR monitoring center. Ethiopia established its own pharmacovigilance system under  
18 the Food and Drug Administration and control authority in 2002. Since the introduction of the  
19 pharmacovigilance system, only a small number of ADRs have been reported to the center [16].  
20 Besides, studies on identifying factors and reasons for poor reporting practices are limited in our  
21 context. The aim of this study was therefore to determine the knowledge, attitudes, and practices  
22 of ADRs reporting and to identify predictive factors for poor ADR reporting practices among  
23 health professionals in a tertiary hospital in the Tigray region, Ethiopia.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Materials and Methods**

### 40 **Study setting and period**

41  
42 The study was conducted at Ayder comprehensive specialized hospital (ACSH), Tigray region,  
43 Northern Ethiopia. ACSH is a teaching and referral hospital with 500 beds. The hospital serves  
44 more than 9 million people in the catchment area. ACSH provides all the specialized and non-  
45 specialized hospital services including emergency services, outpatient services, and inpatient  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 services. Healthcare professionals working in all of these areas were included in this study between  
4  
5 January and March of 2019.  
6

## 7 8 **Study design and population** 9

10 An institutional-based cross-sectional study was conducted. The target populations for this  
11 study were nurses, physicians, and pharmacists working in ACSH during the study periods.  
12  
13 Healthcare professionals who were refused or did not wish to participate in the study were  
14  
15 excluded.  
16  
17  
18

## 19 20 **Sample Size Determination and sampling technique** 21

22 The sample size was calculated using a single proportion sample size estimating formula  
23

$$24 \quad n = \frac{(z_{1-\alpha/2})^2 P(1-P)}{d^2} = \frac{(1.96)^2 0.66(1-0.66)}{0.05^2} = 344.8 \approx 345$$

25  
26  
27  
28 Where, n = sample size, Z = confidence interval (1.96) p = The proportion of health care  
29 professionals with poor knowledge of ADR reporting (65.8, p= 0.66), obtained from a study  
30 conducted in Amhara region of Ethiopia [17], and d = Margin of error to be tolerated (0.05).  
31  
32 By adding 5% (345x0.05 = 17) of the sample size to compensate non-respondents, the total  
33 sample size required was 362. Subjects were recruited using stratified random sampling  
34  
35 technique. A list of HCPs (pharmacists, physicians, and nurses) working at the hospital was  
36  
37 obtained from the hospital's human resources department. All HCPs were first stratified  
38  
39 according to the type of profession and this list was used as a sampling frame. Depending on  
40  
41 the size of the profession in each category of HCPs, participants were randomly selected. We  
42  
43 used a lottery method to randomly select a set of healthcare professionals as respondents from  
44  
45 each category. We used this lottery method from the complete list of each category assuming  
46  
47 that all the HCPs working in a similar profession (for example, all physicians) in different  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 departments and/or units were homogeneous with respect to knowledge, attitude, and practice  
4  
5 of ADRs reporting.  
6

## 7 8 **Outcome measures**

9  
10 In this survey, knowledge of ADR reporting was assessed using nine questions containing  
11  
12 general knowledge about ADR and ADR reporting. Each correct answer had a score of 1 and  
13  
14 each wrong answer had a score of 0. Thus, the total score ranged from 0 to 9 points. The overall  
15  
16 level of knowledge was categorized using the median score. Participants with above median  
17  
18 scores were classified as having good knowledge and below the median scores were classified  
19  
20 as having poor knowledge. Participants' attitudes were assessed using ten items rated as  
21  
22 agreeing, neutral, and disagreeing on a three-point Likert scale. The "agree" responses received  
23  
24 a score of 3, "neutral" a score of 2, and "disagree" a score of 1. An inverted score was made for  
25  
26 the negative-worded questions. Therefore, the maximum possible attitude score was 30. The  
27  
28 median attitude score was calculated for each respondent, on the basis of which their attitude  
29  
30 was categorized as positive and negative. The level of practice of health professionals was  
31  
32 assessed by determining whether they had encountered, documented and reported ADRs or not.  
33  
34 Participants were classified as having good practice if they had reported one or more ADRs and  
35  
36 poor practices, if they had never reported ADR, despite encountering ADRs.  
37  
38  
39  
40  
41

## 42 **Data collection**

43  
44  
45 The Data Collection Tool is a questionnaire that was adopted from similar previous studies on the  
46  
47 knowledge, attitudes, and practices of health care professionals on ADR reporting [18-20].  
48

49  
50 The questionnaire was reviewed for its content validity by consensus of a panel of three experts in  
51  
52 the field derived from academia (one expert from pharmacoepidemiology and two experts from  
53  
54 clinical pharmacy departments). The Index of consistency of the questionnaires was 0.86,  
55  
56  
57

1  
2  
3 suggesting that the questions strictly adhered to the objectives of the study. A pre-test was  
4 performed on 5% of the sample (19 HCPS) in a different hospital and face validity of the  
5 questionnaire was tested. Minor modifications have been made accordingly to avoid ambiguities  
6 and improve clarity. These participants were not included in the final study.  
7  
8  
9  
10  
11

12  
13 The prepared self-administered questionnaire contained four different sections. The first section  
14 contained demographic information. The second section consists of nine questions used to measure  
15 the knowledge of HCPs related to ADR reporting. The third section consisted of ten questions,  
16 which assessed participants' attitudes toward ADR reporting. The fourth section is about the  
17 practice of ADR reporting. The questionnaires were distributed by two pharmacists in person. The  
18 completed questionnaires were then collected by the pharmacists in person at the end of the first,  
19 second, third, and fourth weeks. A remainder was provided to non-respondents twice (i.e. at the  
20 end of the second week and the end of the third week). If the questionnaires did not return by the  
21 end of the fourth week, the participant was considered non-respondent.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 34 35 **Statistical methods**

36  
37 The data were coded, double-entered into Epi data management (version 4.2.0) and statistical  
38 analysis was performed using STATA version 14.1 (STATA Corp, TX, USA). Descriptive  
39 analysis was computed using mean (SD) and median (IQR) for quantitative variables and  
40 frequency for categorical variables. To determine the factors associated with ADR reporting,  
41 univariate and multivariate logistic regression tests were used. The dependent variable was ADR  
42 reporting, while demographics, knowledge, and attitude were included as the independent  
43 variables. Values were considered significant at a p-value of  $<0.05$  ( $\alpha=0.05$ ).  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 54 **Ethical considerations**

The ethical approval and clearance were obtained from the Ethics Review Committee of the School of Pharmacy, College of Health Sciences, Mekelle University (reference number: CHS/161/pharm-11). In addition, a brief description of the objective of the study was provided for all the participants to avoid ambiguity and misunderstanding. The data collection process was initiated after the willingness of the health professionals was requested and formal written consent was obtained.

### **Patient and Public Involvement**

No patient involved

## **Results**

### **Demographic characteristics**

In the current study, 362 questionnaires were distributed. Of these, 307 were duly completed and returned, giving a response rate of 84.8%. Of all respondents, 190 (61.9%) were nurses, 63 (20.5%) were pharmacist, and 54 (17.6%) were physicians. About 50% of respondents have less than five years of experience and more than half of the participants had not received any training on ADRs (table 1).

Table 1: Socio-demographic characteristics of respondents at ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Variable	Frequency (%)
Sex	
Male	156 (50.8)
Female	151 (49.2)
Age	

<25	63(20.5)
25-34	199(64.8)
≥35	45(14.7)
Mean ± SD	29.1 ± 4.3
Median (range)	28 (23-51)
Profession	
Physician	54 (17.6)
Pharmacy	63 (20.5)
Nurse	190 (61.9)
Work experience (years)	
< 5	156 (50.9)
5-9	121 (40)
≥10	28 (9.1)
Trained on ADR reporting	
Yes	138(44.95)
No	169(55.05)

### Knowledge of ADR reporting

There were nine questions assessing knowledge of ADRs. Only 29.3% of respondents knew the exact definition of adverse reactions and 36.8% of respondents knew what to report. A small proportion of respondents (19.5%) were aware of the classification of ADRs. Of the respondents, 39.4% of the respondents felt they were aware of the availability of the National Reporting Center in Ethiopia and a small proportion of the respondents (31.9%) knew where to report. The median with inter-quartile range (IQR) of the level of knowledge of ADRs reporting among HCPs was 4 (3–6). Overall, the majority (58.3%) of health professionals had poor knowledge of ADR reporting (table 2).

Table 2: knowledge of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Variables	Frequency (%)
Which of the following defines ADR correctly?	
Any noxious or undesired effect of drug occurring at normal dose, during normal use*	90 (29.3)
Adverse health outcomes associated with inappropriate drug use	51 (16.6)
Harm resulting from the use of substandard/counterfeit drugs	26 (8.5)
Harm caused by drug overdose	67 (21.8)
All can define ADR	73 (23.8)
Which ADR should be reported?	
All series ADRs	113 (36.8)
ADRs to herbal and non-allopathic drugs	15 (4.9)
ADRs to new drugs	49 (16.0)
ADRs to vaccines drugs	8 (2.6)
Unknown ADRs to old drugs	9 (2.9)
All of the above*	113 (36.8)
The correct classification of the type of ADR	
Type A,B,C,D,E,and F*	60 (19.5)
Type 1,2,3,4,5,6 and 7	62 (20.2)
Known, unknown and common, uncommon	89 (29.0)
Reversible and irreversible	64 (20.8)
Do not know	31 (10.1)
Is there any center /ADR reporting system in Ethiopia	
Yes	121 (39.4)
No	141 (45.9)
Don't know	45 (14.7)
All ADRs are known before a medicine is marketed.	
Yes	99 (32.2)
No*	168 (54.7)
Don't know	40 (13.0)
Are you aware of any drug that banned due to ADR?	
Yes*	98 (31.9)
No	176 (57.3)
Don't know	33 (10.7)
Where are ADRs reported in Ethiopia?	
Manufacturers	17 (5.5)
Ministry of Health of Ethiopia	68 (22.1)
Ethiopian pharmaceutical association	47 (15.3)

DTC of respective health facility	49 (16.0)
FMHACA*	98 (31.9)
Pharmacy dept	28 (9.1)
Do you think that ADR is the same with side effects?	
Yes	127(41.4)
No*	180(58.6)
Which of the following is the major risk factor for the occurrence of maximum ADRs	
Arthritis	30 (9.8)
Renal failure*	147 (47.9)
Visual impairment	24 (7.8)
All of these	106 (34.5)
Overall knowledge score	
Good	128 (41.7)
Poor	179 (58.3)

ADR: Adverse drug reaction, DTC: drug and therapeutic committee STG: standard treatment guideline DACA: Drug Administration and Control Authority, FMHACA: Food, Medicine and Healthcare Administration and Control Authority, \*correct answers

## Attitude of health professionals toward ADR reporting

Regarding healthcare professionals' attitudes to ADRs reporting, the majority (67.4%) of respondents agreed that it is necessary to report, while 37.8% agreed that ADRs reporting should be mandatory. Most respondents (51.1%) disagreed with the idea that only prescribed medication should be reported. The median (IQR) of the attitude score of ADRs reporting among HCPs was 20 (17–22). Overall, about 60% of respondents showed a positive attitude towards ADRs reporting (table 3).

Table 3: Attitude of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Responses		
	Agree, n (%)	Neutral n (%)	Disagree n (%)
ADR reporting is necessary	207 (67.4)	23 (7.5)	77 (25.1)

ADR reporting should be mandatory for all HCPs	116 (37.8)	62 (20.2)	129 (42.0)
ADR reporting increase patient's safety	148 (48.2)	66 (21.5)	93 (30.3)
ADR reporting is important for health care system	135 (44.0)	73 (23.8)	99 (32.2)
There is a need to be sure that ADRs are related to the drug before reporting	194 (63.2)	35 (11.4)	78 (25.4)
Only ADR of prescription drug needs to be reported	82 (26.7)	68 (22.1)	157 (51.1)
One report of ADR makes no differences	103 (33.6)	78 (25.4)	126 (41.0)
The yellow card is difficult to fill up	177 (57.7)	88 (28.7)	42 (13.7)
ADR reporting creates additional workload and it is time consuming	199 (64.8)	78 (25.4)	30 (9.8)
Establishing ADR reporting center in every hospital is important	189 (61.6)	44 (14.3)	74 (24.1)
Overall level of attitude			
Positive	184 (59.9%)		
Negative	123 (40.1%)		

### Practices of health professionals about ADR reporting

Of the 307 health professionals, 74.9% encountered ADR in the last 12 months of their clinical practice, and 29.1% of them recorded in patient cards. Although most health care professionals experienced ADR, only 32.1% reported it (table 4).

Table 4: Practice of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Category	Frequency (%)
Have you ever encountered patient with ADR in your clinical practice in the last 12 months	Yes	230(74.9)
	No	77 (25.1)
How many patients with ADR have you encountered during the last 12 months?	None	77 (25.1)
	One	13 (4.2)
	Two	58 (18.9)
	Three	61 (19.9)



	Four	52 (16.9)
	More than four	46 (15.0)
Have you noted the ADR you encountered on the patient clinical record (n=230)	Yes	67 (29.1)
	No	163 (70.9)
How often do you give advice to your patients on possible ADRs you prescribed, dispensed or administered	Usually	118 (38.4)
	Never	89 (29.0)
	Sometimes	69 (22.5)
	Always	31 (10.1)
If you encountered ADR, have you ever reported the ADR? (n=230)	Yes (good practice)	74 (32.1)
	No (poor practice)	156 (67.9)

### Factors associated with poor ADR reporting practice

A univariable logistic regression analysis was performed to determine the association of each variable with the practice of ADR reporting. In the univariable analysis work experience of the HCPs ( $\geq 10$  years) (unadjusted odds ratios (OR) = 0.31, 95% CI: 0.15- 0.64), negative attitude (unadjusted OR = 2.08, 95% CI: 1.17-3.72), poor knowledge (unadjusted OR= 3.49, 95% CI: 1.95- 6.23), lack of training on ADR reporting (unadjusted OR= 7.67, 95% CI: 4.07- 14.46), and nursing profession (unadjusted OR= 2.11, 95% CI: 1.06- 4.20), were associated with poor ADR reporting practice. A subsequent multivariable logistic regression model was conducted to identify the independent predictors. The full model containing all predictors was statistically significant ( $X^2 = 69.78$ ,  $df = 10$ ,  $P$ -value  $< 0.001$ ). The results of the multivariate logistic regression indicated that only work experience of the HCPs ( $\geq 10$  years ) (adjusted odds ratios (AOR)= 0.36, 95% CI: 0.13- 0.97), poor knowledge (AOR= 2.63, 95% CI: 1.26- 5.45), and lack of training on ADR reporting (AOR= 7.31, 95% CI: 3.42- 15.62) were the predictors of poor ADR reporting practice (table 5).

Table 5: Univariable and multivariable logistic regression analysis of associated factors of poor ADR reporting practice in Tigray Region, Ethiopia from January 2019 to March 2019 (n=230)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Variable	ADR reporting practice		P value	COR (95% CI)	AOR (95% CI)	P value
	Yes, n (%)	No, n (%)				
<b>Gender</b>						
Male	44 (59.5)	73 (46.8)		1	1	
Female	30 (40.5)	83 (53.2)	0.07	1.67(0.95, 2.92)	1.51(0.77, 2.94)	0.23
<b>Age (years)</b>						
<25	15(20.3)	29(18.6)		1		
25-34	48(64.9)	100(64.1)	0.84	1.09(0.53, 2.19)	1.22(0.46, 3.23)	0.68
≥35	11(14.9)	27(17.3)	0.12	1.27(0.49, 3.24)	3.40(0.93, 12.48)	0.07
<b>Experience (years)</b>						
< 5	27(36.5)	84(53.8)		1	1	
5-9	24(32.4)	50(32.1)	0.23	0.67(0.35, 1.28)	1.42(0.57, 3.52)	0.45
≥10	23(31.1)	22(14.1)	0.001	0.31(0.15, 0.64)	0.36(0.13, 0.97)	0.04
<b>Profession</b>						
Pharmacist	20(27.0)	26(16.7)		1	1	
Physician	16(21.6)	26(16.7)	0.61	1.25(0.53, 2.93)	2.15(0.70, 6.56)	0.18
Nurse	38(51.4)	104(66.7)	0.04	2.11(1.06, 4.20)	1.36(0.57, 3.26)	0.49
<b>Attitude</b>						
Positive	50(67.6)	78(50)		1	1	
Negative	24(32.4)	78(50)	0.01	2.08 (1.17, 3.72)	1.24(0.59, 2.59)	0.57
<b>Knowledge</b>						
Good	48(64.9)	54(34.6)		1	1	
Poor	26(35.1)	102 (65.4)	<0.001	3.49(1.95, 6.23)	2.63(1.26, 5.45)	0.01
<b>Training provided</b>						
Yes	56(75.7)	45(28.8)		1	1	
No	18(24.3)	111(71.2)	<0.001	7.67(4.07, 14.46)	7.31(3.42, 15.62)	<0.001

ADR: adverse drug reaction, AOR: adjusted odds ratio, COR: crude odds ratio

## Discussion

One of the main goals of this study was to investigate the knowledge of HCPs towards ADRs reporting. This issue is critical for research to identify the necessary interventions, as HCPs cannot effectively participate in the reporting without sufficient knowledge of the ADR and its reporting process. We found that only 41.7 % of HCPs had good knowledge about ADR reporting, similar to the reports seen in Amhara region of Ethiopia (47%) [21] and West Ethiopia (48 %) [22]. The reason for insufficient knowledge of ADRs reporting in these studies may be due to the poor access to information about ADR reporting and the lack of adequate training in this area, which allows them to acquire and integrate their knowledge of ADR reporting throughout the course of their clinical service [21, 23]. In addition, the low level of knowledge could be the result of insufficient provision of undergraduate training in pharmacovigilance, which may help prepare HCPs for the task of ADRs monitoring and reporting in their future careers. The lack of continuous medical education in this area could also contribute to poor knowledge of ADRs reporting.

The level of knowledge of ADRs reporting in our study was also lower compared to previous findings reported in the Philippines (77%) [24] and Kuwait (61.5%) [25]. This discrepancy may be due to differences in government involvement in national pharmacovigilance programs, study participants, and training level. The current study was conducted in a system where national ADR reporting methods were in its infancy and most HCPs (55%) did not receive any ADR reporting training.

Our study showed that 39.4% of HCPs were aware of the existence of an ADR system in Ethiopia. This meant that most of the participants did not have information about the authority responsible for monitoring ADR in Ethiopia. This is similar to the study conducted in Addis Ababa, Saudi Arabia, and Jordan, which reported lack of knowledge about the national ADR reporting system

1  
2  
3 [26-28]. This is a critical observation, which is undoubtedly related to the current underreporting  
4 of ADRs. In addition, only 31.9 % of the HCPs know where to report ADR. This could be as a  
5 result of limited awareness and support for ADR monitoring. Awareness-raising programs through  
6 advertising would appear necessary to improve ADRs reporting in our setting.  
7  
8  
9

10  
11  
12  
13 Regarding the level of attitude, we found that about 60 % of HCPs had a positive attitude on ADR  
14 and its reporting. Although the majority of the respondents had positive attitude, the result is lower  
15 compared to previous findings in Amhara region of Ethiopia (86%) [21]. This shows though there  
16 is some positivity in the attitude of HCPs towards ADRs reporting, the attitude level still could be  
17 enhanced. Most respondents (67.4%) felt that adverse reactions reporting is necessary, which is  
18 consistent with previous studies [20, 21]. However, 64.8% of the respondents agreed that reporting  
19 creates an additional workload, which is higher than the results obtained in the Amhara region  
20 (32.4%) [21]. Although it may take some time to complete the report forms, the high proportion  
21 of respondents with such perception found in our study may affect the motivation to report adverse  
22 reactions. Healthcare professionals should consider ADRs reporting as an obligation and should  
23 be aware of the existing pharmacovigilance systems.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 Another important finding was that ADRs reporting practices among HCPs were very poor.  
40 Although more than 75% of respondents encountered one or more ADRs in their daily practice,  
41 only 32.1% of respondents reported ADRs. This is consistent with a study conducted in Amhara  
42 Region of Ethiopia and south India [29, 30]. Insufficient promotion of ADR reporting, poor  
43 distribution of ADR reporting forms, lack of knowledge, and lack of training were mentioned as  
44 factors for major cause of underreporting [12, 21].  
45  
46  
47  
48  
49  
50  
51  
52

53 The study also identified the predictors of poor ADR reporting practices. Less experienced HCPs  
54 were more likely to have poor ADR reporting practices. This finding is consistent with a study  
55  
56  
57

1  
2  
3 conducted in Uganda, where more experienced HCPs were four times more likely to have ever  
4 reported than less experienced professionals [30]. Health professionals with poor knowledge were  
5 more likely to have a poor practice of ADRs reporting. The association of poor knowledge levels  
6  
7 of health professionals with poor ADR reporting practice has been observed in many similar  
8 previous studies [30-34]. Moreover, health professionals who had not received ADRs reporting  
9 training were more likely to have poor practice. This is also supported by a study carried out in  
10 Spain [35]. However, only 44.95% of the respondents were trained in our study. Similarly, HCPs  
11 have shown limited training in areas of ADR and their reporting in studies conducted in Sudan  
12 [32] and Uganda [30]. Thus, more training regarding the identification of ADR, the purpose of the  
13 ADR reporting, and the availability of resources for ADR reporting is required.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 These findings have important implications. The low level of knowledge of the ADR and its  
29 reporting among HCPs should be enhanced by designing different strategies. A systematic review  
30 of strategies to improve ADRs reporting has shown that multiple interventions appear to have had  
31 more impact than single interventions [13]. Several studies have shown improved knowledge and  
32 attitude scores after educational interventions, including oral workshops, oral presentations, group  
33 discussions, designing ADR newsletters in hospitals, and ongoing training in pharmacovigilance  
34 and ADR reporting [36-40]. Other studies have shown that ADRs reporting has been improved by  
35 offering incentives to health professionals [41, 42]. A study conducted in Spanish that involves  
36 both economic incentives and educational activities, resulted in up to a six-fold increase in the  
37 average ADR reporting [43]. Increasing the availability of yellow cards on wards as well as  
38 encouragement to use web-based reporting had improved reporting rates [44]. Therefore,  
39 empowering HCPs in detecting and reporting suspected drug reactions and using strategies that  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 are evidence-based is essential to strengthening pharmacovigilance systems in Ethiopia. This is  
4 especially important for less experienced health professionals and for those who had never  
5 received training on ADR reporting. However, additional research needs to be done to investigate  
6 the impact of these interventions on the knowledge and practice of ADR reporting in our setting.  
7  
8  
9  
10  
11  
12  
13

14 Finally, there are several limitations to this study. We used a self-report as the main method of  
15 inquiry, which may have introduced recall bias. The HCPs may have made explicit responses to  
16 the fear that they would be embarrassed if they did not report ADRs. However, because we used  
17 self-administered questionnaires without respondents' names, the potential for this bias was  
18 reduced. The cross-sectional design we used may not establish a causal relationship between ADR  
19 reporting and explanatory variables. Finally, the study was conducted in a tertiary referral hospital  
20 and may not be generalized for all HCPs in different health care levels in the country. Despite  
21 these limitations, our study has generated important insights on knowledge, attitude, and practice  
22 of ADR reporting and predictors of poor ADRs reporting practice.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

The majority of health professionals had poor knowledge and practice, but a positive attitude toward ADRs reporting. Poor knowledge, less work experience and lack of training were predictors of poor ADR reporting practice. Therefore, strategies to improve knowledge and practices regarding ADR reporting should be implemented. Training should be provided to all HCPs, especially those who have never received training and less experienced professionals.

## Acknowledgments

The authors would like to thank the College of Health Science, Mekelle University for their support and cooperation. The authors would also like to thank for all Ayder comprehensive specialized hospital staff members for their willingness to participate and dedicate their valuable time to fill the questionnaire

**Contributors:** KG and MS conceived the study and drafted the manuscript and contributed to data entry, data analysis, draft manuscript and final proof reading. BYH, SWA and YLN participated in study design, data analysis and in the process of manuscript writing. All authors approved the final manuscript.

## Data Availability

The dataset of this study is available from the corresponding author upon request.

## Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

## Conflicts of Interest

The authors have declared that there is no conflict of interests with respect to the authorship and/or publication of this study.

**Participant consent:** Obtained.

## References

1. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. *Drug safety*. 2015;38(5):437-53. Epub 2015/03/31. doi: 10.1007/s40264-015-0281-0. PubMed PMID: 25822400; PubMed Central PMCID: PMC4412588.
2. Campbell JE, Gossell-Williams M, Lee MG. A Review of Pharmacovigilance. *West Indian Med J*. 2014;63(7):771-4. Epub 03/05. doi: 10.7727/wimj.2013.251. PubMed PMID: 25867582.
3. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. *Drug safety*. 2016;39(9):847-57. Epub 2016/07/28. doi: 10.1007/s40264-016-0444-7. PubMed PMID: 27449638.
4. Organization WH. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. Geneva: World Health Organization, 2002.
5. Huang Y-L, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. *Drug safety*. 2014;37(8):581-96. Epub 07/15. doi: 10.1007/s40264-014-0194-3. PubMed PMID: 25022829.
6. Sabblah GT, Akweongo P, Darko D, Dodoo ANO, Sulley AM. Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana. *Ghana Med J*. 2014;48(4):189-93. PubMed PMID: 25709133.



- 1  
2  
3 7. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review.  
4 Drug safety. 2006;29(5):385-96. Epub 2006/05/13. doi: 10.2165/00002018-200629050-00003.  
5 PubMed PMID: 16689555.  
6
- 7  
8 8. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of  
9 adverse drug reactions: a systematic review. Drug safety. 2009;32(1):19-31. Epub 2009/01/10.  
10 doi: 10.2165/00002018-200932010-00002. PubMed PMID: 19132802.  
11
- 12  
13 9. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal  
14 products because of adverse drug reactions: a systematic review of the world literature. BMC  
15 medicine. 2016;14:10. Epub 2016/02/05. doi: 10.1186/s12916-016-0553-2. PubMed PMID:  
16 26843061; PubMed Central PMCID: PMC4740994.  
17
- 18  
19 10. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications  
20 for pharmacists. Ther Clin Risk Manag. 2005;1(3):181-8. Epub 09/. PubMed PMID: 18360558.  
21
- 22  
23 11. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse  
24 drug reactions: a systematic review. British journal of clinical pharmacology. 2017;83(4):875-83.  
25 Epub 2016/11/22. doi: 10.1111/bcp.13159. PubMed PMID: 27868226; PubMed Central PMCID:  
26 PMC4740994.  
27
- 28  
29 12. Perez Garcia M, Figueras A. The lack of knowledge about the voluntary reporting system  
30 of adverse drug reactions as a major cause of underreporting: direct survey among health  
31 professionals. Pharmacoepidemiology and drug safety. 2011;20(12):1295-302. Epub 2011/07/28.  
32 doi: 10.1002/pds.2193. PubMed PMID: 21793098.  
33
- 34  
35 13. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to  
36 improve adverse drug reaction reporting: a critical and systematic review. Drug safety.  
37 2013;36(5):317-28. Epub 2013/05/04. doi: 10.1007/s40264-013-0058-2. PubMed PMID:  
38 23640659.  
39
- 40  
41 14. Alshammari TM, Alamri KK, Ghawa YA, Alohal NF, Abualkol SA, Aljadhey HS.  
42 Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in  
43 Saudi Arabia. International journal of clinical pharmacy. 2015;37(6):1104-10. Epub 2015/07/29.  
44 doi: 10.1007/s11096-015-0165-5. PubMed PMID: 26216270.  
45
- 46  
47 15. Alshami MAAAM, Azm MIMIM. The need of pharmacovigilance activities in Yemen.  
48 Global Journal of Medical Research. 2014.  
49  
50  
51  
52  
53  
54  
55  
56  
57

16. Mulatu WN, Worku A. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. *Journal of Pharmacovigilance*. 2014.
17. Necho Mulatu W. Assessment of Knowledge, Attitude and Practice of Health Professionals towards Adverse Drug Reaction Reporting and Factors Associated with Reporting 2014.
18. Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. *Saudi Pharm J*. 2018;26(4):453-61. Epub 2018/05/31. doi: 10.1016/j.jsps.2018.02.014. PubMed PMID: 29844715; PubMed Central PMCID: PMC5961757.
19. Guner MD, Ekmekci PE. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. *Journal of drug assessment*. 2019;8(1):13-20. Epub 2019/02/08. doi: 10.1080/21556660.2019.1566137. PubMed PMID: 30729064; PubMed Central PMCID: PMC6352929.
20. Shanko H, Abdela J. Knowledge, Attitudes, and Practices of Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study. *Hospital pharmacy*. 2018;53(3):177-87. Epub 2018/08/28. doi: 10.1177/0018578717737430. PubMed PMID: 30147138; PubMed Central PMCID: PMC6102784.
21. Seid MA, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals' knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. *International journal of clinical pharmacy*. 2018;40(4):895-902. Epub 2018/08/11. doi: 10.1007/s11096-018-0682-0. PubMed PMID: 30094559.
22. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. *BioMed research international*. 2016;2016.
23. Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse drug reaction monitoring in Ethiopia: Analysis of case reports, 2002-2007. *Ethiopian Journal of Health Development*. 2011;25(2):168-73.

- 1  
2  
3 24. Carandang RR, Cao K, Jose NB, Almonte FD, Tinio RM. Research article knowledge  
4 and attitudes on adverse drug reaction reporting of selected hospital-based health practitioners in  
5 Manila, Philippines. *Sch Acad J Pharm (SAJP)*. 2015;4:301-7.  
6  
7
- 8 25. Alsaleh FM, Alzaid SW, Abahussain EA, Bayoud T, Lemay J. Knowledge, attitude and  
9 practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working  
10 in secondary and tertiary governmental hospitals in Kuwait. *Saudi Pharm J*. 2017;25(6):830-7.  
11  
12 Epub 2017/09/28. doi: 10.1016/j.jsps.2016.12.004. PubMed PMID: 28951666; PubMed Central  
13 PMCID: PMC5605890.  
14  
15
- 16 26. Goshime A. *Assessment of Knowledge, Attitude and Practices on Adverse Drug  
17 Reaction Reporting among Pharmacy Personnel Working at Community Pharmacy, Addis  
18 Ababa, Ethiopia*: Addis Ababa University; 2015.  
19  
20
- 21 27. Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, et al.  
22 Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction  
23 reporting in Saudi Arabia. *Saudi pharmaceutical journal*. 2014;22(5):411-8.  
24  
25
- 26 28. Katekhaye VM, Kadhe NG, John J, Pawar SR. Knowledge, attitude and practice of  
27 pharmacovigilance among medical professionals at a tertiary care hospital in Mumbai,  
28 Maharashtra, India. *Int J Res Med Sci*. 2016;5:156-61.  
29  
30
- 31 29. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the  
32 knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals  
33 in a teaching hospital in South India. *Perspectives in clinical research*. 2015;6(1):45.  
34  
35
- 36 30. Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health  
37 care workers at Mulago National Referral and Teaching hospital in Uganda. *Afr Health Sci*.  
38 2015;15(4):1308-17.  
39  
40
- 41 31. Ohaju-Obodo J, Iribhogbe O. Extent of pharmacovigilance among resident doctors in  
42 Edo and Lagos states of Nigeria. *Pharmacoepidemiology and drug safety*. 2010;19(2):191-5.  
43  
44
- 45 32. Elnour AA, Ahmed AD, Yousif MAE, Shehab A. Awareness and reporting of adverse  
46 drug reactions among health care professionals in Sudan. *The Joint Commission Journal on  
47 Quality and Patient Safety*. 2009;35(6):324-AP2.  
48  
49
- 50 33. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. *Drug safety*.  
51 2006;29(5):385-96.  
52  
53  
54  
55  
56  
57

- 1  
2  
3 34. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital  
4 pharmacists to adverse drug reaction reporting. *British journal of clinical pharmacology*.  
5 2001;51(1):81-6.  
6  
7  
8 35. Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernandez-Diaz S, Lasheras B. Factors  
9 that influence under-reporting of suspected adverse drug reactions among community  
10 pharmacists in a Spanish region. *Drug safety*. 2007;30(11):1073-82.  
11  
12 36. Jha N, Rathore DS, Shankar PR, Bhandary S, Pandit RB, Gyawali S, et al. Effect of an  
13 educational intervention on knowledge and attitude regarding pharmacovigilance and consumer  
14 pharmacovigilance among community pharmacists in Lalitpur district, Nepal. *BMC research*  
15 *notes*. 2017;10(1):4.  
16  
17 37. Bisht M, Singh S, Dhasmana D. Effect of educational intervention on adverse drug  
18 reporting by physicians: a cross-sectional study. *ISRN pharmacology*. 2014;2014.  
19  
20 38. Li Q, Zhang S-M, Chen H-T, Fang S-p, Yu X, Liu D, et al. Awareness and attitudes of  
21 healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. *Chinese*  
22 *medical journal*. 2004;117(6):856-61.  
23  
24 39. Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge  
25 attitude practice of pharmacovigilance among health care professionals in an Indian tertiary care  
26 teaching hospital. *Int J Pharm Tech Res*. 2011;3(2):678-92.  
27  
28 40. Khalili H, Mohebbi N, Hendoiee N, Keshtkar A-A, Dashti-Khavidaki S. Improvement of  
29 knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical  
30 pharmacists' interventional study. *BMJ open*. 2012;2(1):e000367. doi: 10.1136/bmjopen-2011-  
31 000367.  
32  
33 41. Ali S, Egunsola O, Al-Dossari DS, Al-Zaagi IA. Adverse drug reaction reporting in a  
34 large tertiary hospital in Saudi Arabia: results of an incentive strategy. *Therapeutic advances in*  
35 *drug safety*. 2018;9(10):585-90. Epub 2018/10/05. doi: 10.1177/2042098618790209. PubMed  
36 PMID: 30283626; PubMed Central PMCID: PMC6166318.  
37  
38 42. Chang F, Xi Y, Zhao J, Zhang X, Lu Y. A time series analysis of the effects of financial  
39 incentives and mandatory clinical applications as interventions to improve spontaneous adverse  
40 drug reaction reporting by hospital medical staff in China. *Journal of evaluation in clinical*  
41 *practice*. 2017;23(6):1316-21. Epub 2017/07/05. doi: 10.1111/jep.12780. PubMed PMID:  
42 28675578.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 43. Pedros C, Vallano A, Cereza G, Mendoza-Aran G, Agusti A, Aguilera C, et al. An  
4 intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a  
5 time series analysis in Spain. *Drug safety*. 2009;32(1):77-83. Epub 2009/01/10. doi:  
6 10.2165/00002018-200932010-00007. PubMed PMID: 19132807.  
7  
8 44. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: Systematic  
9 review. *Clin Epidemiol*. 2009;1:75-92. PubMed PMID: 20865089.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	4 and 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	--
		(c) Explain how missing data were addressed	--
		(d) If applicable, describe analytical methods taking account of sampling strategy	--
		(e) Describe any sensitivity analyses	--
<b>Results</b>			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	---
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	--
Outcome data	15*	Report numbers of outcome events or summary measures	7-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	---
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	---
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13 and 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034553.R2
Article Type:	Original research
Date Submitted by the Author:	13-Jan-2020
Complete List of Authors:	gidey, kidu; Mekelle University College of Health Sciences, clinical pharmacy; seifu, mohammedamin; Mekelle University, clinical pharmacy Hailu, Berhane; Mekelle University, Pharmacy Asgedom, Solomon Weldegebreal; School of Pharmacy, Mekelle University Niriayo, yirga; Mekelle University, clinical pharmacy
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Health services research, Medical education and training, Pharmacology and therapeutics
Keywords:	Adverse drug reaction, healthcare professionals, knowledge, practice

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study

Kidu Gidey<sup>1\*</sup>, Mohammedamin Seifu<sup>1</sup>, Berhane Yohannes Hailu<sup>1</sup>, Solomon Weldegebreal Asgedom<sup>1</sup>, Yirga Legesse Niriayo<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

\*Corresponding author: Kidu Gidey; [kidupharm@gmail.com](mailto:kidupharm@gmail.com) (KG)

## Abstract

**Objective:** This study aimed to assess the knowledge, attitude, and practice of adverse drug reactions (ADRs) reporting and identify factors associated with ADRs reporting among healthcare professionals (HCPs) working in Tigray region, Ethiopia.

**Materials and Methods:** A cross-sectional study was conducted between January and March of 2019 in a tertiary care hospital in Tigray region, Ethiopia. A self-administered, pretested questionnaire was administered to HCPs. Data were summarized using descriptive statistics. Logistic regression analysis was used to identify factors associated with poor ADRs reporting practices.

**Results:** In total, 362 questionnaires were distributed, and the response rate was 84.8% (n = 307). Of all respondents, 190 (61.9%) were nurses, 63 (20.5%) were pharmacist, and 54 (17.6%) were physicians. About 58.3% of HCPs had poor knowledge of ADRs reporting. The majority of the respondents had a positive attitude (59.9%), and only a few (32.1%) respondents have good ADRs reporting practices. Poor knowledge (Adjusted odds ratio (AOR)= 2.63, 95% confidence interval (CI): 1.26- 5.45), and lack of training on ADRs reporting (AOR= 7.31, 95%

1  
2  
3 CI: 3.42- 15.62) were both negatively associated with ADRs reporting practice, whereas higher  
4  
5 work experience ( $\geq 10$  years) (AOR= 0.36, 95% CI: 0.13- 0.97) were positively associated with  
6  
7 ADRs reporting practice.  
8  
9

10 **Conclusions:** The majority of healthcare professionals had poor knowledge and practice, but a  
11  
12 positive attitude toward ADRs reporting. Poor knowledge, less work experience and lack of  
13  
14 training were associated with poor ADRs reporting practice. Hence, strategies to improve the  
15  
16 knowledge and practice of ADRs reporting should be implemented, particularly for untrained and  
17  
18 less experienced HCPs.  
19  
20

21  
22 **Keywords:** Adverse drug reaction, healthcare professionals, knowledge, practice  
23  
24  
25

## 26 **Strengths and limitations of this study**

- 27  
28 • As strengths, this study included a good number of HCPs and includes nurses and  
29  
30 pharmacists as well as physicians.
- 31  
32 • Data collection was conducted prospectively and adjustment for confounding factors was  
33  
34 performed with logistic regression analysis.
- 35  
36 • There is a possibility that HCPs may not report their actual ADRs reporting practices  
37  
38 since the information was self-reported.
- 39  
40 • The cross-sectional design of this study may not establish a causal relationship between  
41  
42 ADRs reporting and explanatory variables.
- 43  
44 • Our study was conducted in a single center and may not be generalizable to HCPs in  
45  
46 other hospitals.  
47  
48  
49  
50  
51

## 52 **Introduction**

1  
2  
3 Adverse drug reactions (ADRs) are a major cause of morbidity and mortality and contribute to the  
4 occurrence of adverse events, leading to increased healthcare costs [1]. ADRs have become a major  
5 public health problem in developing countries [2]. The median prevalence (with interquartile range  
6 [IQR]) of ADR-related hospitalization in developing countries was 5.5% (1.1-16.9) [3]. The  
7 information collected during the pre-marketing phase of drug development is inevitably  
8 incomplete concerning possible ADRs. This is due to the participation of a limited and selected  
9 number of patients who are studied before marketing, the conditions of drug use in clinical trials  
10 are different from those of clinical practice, the duration of the clinical trials is short, and high-  
11 risk patients (such as elderly patients) are often excluded [4]. Therefore, post-marketing  
12 surveillance is important to allow detection of less common, but sometimes very serious ADRs.  
13  
14 Once a drug is registered and marketed, adverse reaction studies can be conducted using a variety  
15 of methods, such as observational studies, monitoring of prescription events, spontaneous reports  
16 and so on [5]. However, the health care system relies heavily on spontaneous ADRs reporting to  
17 monitor drug safety throughout the population during actual use [6].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 A spontaneous reporting system of ADRs is fundamental to effectively discover new adverse  
39 reactions but under-reporting is its major limitations [7, 8]. A systematic review of studies  
40 conducted in the European Union showed a significant and widespread healthcare professionals  
41 under-reporting of ADRs with a median rate of under-reporting of 94% [7]. The low rates of ADRs  
42 reporting may delay regulatory actions to remove drugs with an unacceptable safety profile from  
43 the marketplace. A worldwide systematic review of 462 medicines removed from the market for  
44 safety reasons showed that the median interval between the first reported adverse reaction and the  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 year of first withdrawal was 6 years (IQR, 1-15) and the interval did not consistently shorten over  
4  
5 time [9].  
6

7  
8 Healthcare professionals (HCPs) are responsible for identifying, documenting and ADRs  
9  
10 reporting. Their contribution to the early detection and reporting of ADR is essential [10].  
11  
12 However, ADR reporting is affected by many factors, including lack of awareness, ambiguity  
13  
14 about who should report, difficulties with reporting procedures, lack of feedback on submitted  
15  
16 reports, rapid resolution of adverse events, and so on [11, 12]. The knowledge and attitudes of  
17  
18 health professionals are strongly related to ADRs reporting [8, 13]. Therefore, it is very important  
19  
20 to understand the knowledge and practice of health care providers related to ADR reporting to  
21  
22 improve reporting practices [14].  
23  
24  
25  
26  
27

28  
29 Although local regulatory authorities can make drug safety decisions using ADR data from other  
30  
31 countries, it is essential to take into account a number of factors, such as local population traditions,  
32  
33 genetics, diet, environmental factors, etc [15]. Therefore, it is very important to establish a local  
34  
35 functional ADR monitoring center. Ethiopia established its own pharmacovigilance system under  
36  
37 the Food and Drug Administration and control authority in 2002. Since the introduction of the  
38  
39 pharmacovigilance system, only a small number of ADRs have been reported to the center [16].  
40  
41 Besides, studies on identifying factors and reasons for poor reporting practices are limited in our  
42  
43 context. The aim of this study was therefore to determine the knowledge, attitudes, and practices  
44  
45 of ADRs reporting and to identify predictive factors for poor ADR reporting practices among  
46  
47 health professionals in a tertiary hospital in the Tigray region, Ethiopia.  
48  
49  
50

## 51 52 **Materials and Methods**

### 53 54 **Study setting and period**

1  
2  
3 The study was conducted at Ayder comprehensive specialized hospital (ACSH), Tigray region,  
4 Northern Ethiopia. ACSH is a teaching and referral hospital with 500 beds. The hospital serves  
5 more than 9 million people in the catchment area. ACSH provides all the specialized and non-  
6 specialized hospital services including emergency services, outpatient services, and inpatient  
7 services. Healthcare professionals working in all of these areas were included in this study between  
8 January and March of 2019.  
9

### 16 **Study design and population**

17 An institutional-based cross-sectional study was conducted. The target populations for this  
18 study were nurses, physicians, and pharmacists working in ACSH during the study periods.  
19 Healthcare professionals who were refused or did not wish to participate in the study were  
20 excluded.  
21  
22  
23  
24  
25  
26  
27

### 28 **Sample Size Determination and sampling technique**

29 The sample size was calculated using a single proportion sample size estimating formula

$$30 \quad n = \frac{(z_{1-\alpha/2})^2 P(1-P)}{d^2} = \frac{(1.96)^2 0.66(1-0.66)}{0.05^2} = 344.8 \approx 345$$

31  
32  
33  
34  
35  
36  
37 Where, n = sample size, Z = confidence interval (1.96) p = The proportion of health care  
38 professionals with poor knowledge of ADR reporting (65.8, p= 0.66), obtained from a study  
39 conducted in Amhara region of Ethiopia [17], and d = Margin of error to be tolerated (0.05).  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
By adding 5% (345x0.05 = 17) of the sample size to compensate non-respondents, the total  
sample size required was 362. Subjects were recruited using stratified random sampling  
technique. A list of HCPs (pharmacists, physicians, and nurses) working at the hospital was  
obtained from the hospital's human resources department. All HCPs were first stratified  
according to the type of profession and this list was used as a sampling frame. Depending on

1  
2  
3 the size of the profession in each category of HCPs, participants were randomly selected. We  
4 used a lottery method to randomly select a set of healthcare professionals as respondents from  
5 each category. We used this lottery method from the complete list of each category assuming  
6 that all the HCPs working in a similar profession (for example, all physicians) in different  
7 departments and/or units were homogeneous with respect to knowledge, attitude, and practice  
8 of ADRs reporting.  
9

### 16 **Outcome measures**

17  
18  
19 In this survey, knowledge of ADR reporting was assessed using nine questions containing  
20 general knowledge about ADR and ADR reporting. Each correct answer had a score of 1 and  
21 each wrong answer had a score of 0. Thus, the total score ranged from 0 to 9 points. The overall  
22 level of knowledge was categorized using the median score. Participants with above median  
23 scores were classified as having good knowledge and below the median scores were classified  
24 as having poor knowledge. Participants' attitudes were assessed using ten items rated as  
25 agreeing, neutral, and disagreeing on a three-point Likert scale. The "agree" responses received  
26 a score of 3, "neutral" a score of 2, and "disagree" a score of 1. An inverted score was made for  
27 the negative-worded questions. Therefore, the maximum possible attitude score was 30. The  
28 median attitude score was calculated for each respondent, on the basis of which their attitude  
29 was categorized as positive and negative. The level of practice of health professionals was  
30 assessed by determining whether they had encountered, documented and reported ADRs or not.  
31 Participants were classified as having good practice if they had reported one or more ADRs and  
32 poor practices, if they had never reported ADR, despite encountering ADRs.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Data collection**

1  
2  
3 The Data Collection Tool is a questionnaire that was adopted from similar previous studies on the  
4 knowledge, attitudes, and practices of health care professionals on ADR reporting [18-20].  
5  
6

7  
8 The questionnaire was reviewed for its content validity by consensus of a panel of three experts in  
9  
10 the field derived from academia (one expert from pharmacoepidemiology and two experts from  
11  
12 clinical pharmacy departments). The Index of consistency of the questionnaires was 0.86,  
13  
14 suggesting that the questions strictly adhered to the objectives of the study. A pre-test was  
15  
16 performed on 5% of the sample (19 HCPS) in a different hospital and face validity of the  
17  
18 questionnaire was tested. Minor modifications have been made accordingly to avoid ambiguities  
19  
20 and improve clarity. These participants were not included in the final study.  
21  
22  
23

24  
25 The prepared self-administered questionnaire contained four different sections. The first section  
26  
27 contained demographic information. The second section consists of nine questions used to measure  
28  
29 the knowledge of HCPs related to ADR reporting. The third section consisted of ten questions,  
30  
31 which assessed participants' attitudes toward ADR reporting. The fourth section is about the  
32  
33 practice of ADR reporting. The questionnaires were distributed by two pharmacists in person. The  
34  
35 completed questionnaires were then collected by the pharmacists in person at the end of the first,  
36  
37 second, third, and fourth weeks. A remainder was provided to non-respondents twice (i.e. at the  
38  
39 end of the second week and the end of the third week). If the questionnaires did not return by the  
40  
41 end of the fourth week, the participant was considered non-respondent.  
42  
43  
44  
45

## 46 **Statistical methods**

47  
48

49 The data were coded, double-entered into Epi data management (version 4.2.0) and statistical  
50  
51 analysis was performed using STATA version 14.1 (STATA Corp, TX, USA). Descriptive  
52  
53 analysis was computed using mean (SD) and median (IQR) for quantitative variables and  
54  
55 frequency for categorical variables. To determine the factors associated with ADR reporting,  
56  
57



1  
2  
3 univariate and multivariate logistic regression tests were used. The dependent variable was ADR  
4 reporting, while demographics, knowledge, and attitude were included as the independent  
5 variables. Values were considered significant at a p-value of  $<0.05$  ( $\alpha=0.05$ ).  
6  
7

## 8 9 10 **Ethical considerations**

11  
12 The ethical approval and clearance were obtained from the Ethics Review Committee of the School  
13 of Pharmacy, College of Health Sciences, Mekelle University (reference number:  
14  
15 CHS/161/pharm-11). In addition, a brief description of the objective of the study was provided  
16  
17 for all the participants to avoid ambiguity and misunderstanding. The data collection process was  
18  
19 initiated after the willingness of the health professionals was requested and formal written consent  
20  
21 was obtained.  
22  
23  
24  
25  
26  
27  
28

## 29 **Patient and Public Involvement**

30  
31  
32 As the study focused on the knowledge, attitudes and practices of healthcare professionals, patients  
33 or members of the public were not directly involved in the design or planning of this research  
34  
35 study.  
36  
37  
38  
39

## 40 41 **Results**

### 42 43 **Demographic characteristics**

44  
45 In the current study, 362 questionnaires were distributed. Of these, 307 were duly completed and  
46  
47 returned, giving a response rate of 84.8%. Of all respondents, 190 (61.9%) were nurses, 63 (20.5%)  
48  
49 were pharmacist, and 54 (17.6%) were physicians. About 50% of respondents have less than five  
50  
51  
52  
53  
54  
55  
56  
57

years of experience and more than half of the participants had not received any training on ADRs (table 1).

Table 1: Socio-demographic characteristics of respondents at ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Variable	Frequency (%)
<b>Sex</b>	
Male	156 (50.8)
Female	151 (49.2)
<b>Age</b>	
<25	63(20.5)
25-34	199(64.8)
≥35	45(14.7)
Mean ± SD	29.1 ± 4.3
Median (range)	28 (23-51)
<b>Profession</b>	
Physician	54 (17.6)
Pharmacy	63 (20.5)
Nurse	190 (61.9)
<b>Work experience (years)</b>	
< 5	156 (50.9)
5-9	121 (40)
≥10	28 (9.1)
<b>Trained on ADR reporting</b>	
Yes	138(44.95)
No	169(55.05)

### Knowledge of ADR reporting

There were nine questions assessing knowledge of ADRs. Only 29.3% of respondents knew the exact definition of adverse reactions and 36.8% of respondents knew what to report. A small

1  
2  
3 proportion of respondents (19.5%) were aware of the classification of ADRs. Of the respondents,  
4  
5 39.4% of the respondents felt they were aware of the availability of the National Reporting Center  
6  
7 in Ethiopia and a small proportion of the respondents (31.9%) knew where to report. The median  
8  
9 with inter-quartile range (IQR) of the level of knowledge of ADRs reporting among HCPs was 4  
10  
11 (3–6). Overall, the majority (58.3%) of health professionals had poor knowledge of ADR reporting  
12  
13 (table 2).  
14  
15  
16  
17

18 Table 2: knowledge of healthcare professionals toward ADR reporting in ACSH, Tigray Region,  
19  
20 Northern Ethiopia, from January 2019 to March 2019 (n=307)  
21

Variables	Frequency (%)
Which of the following defines ADR correctly?	
Any noxious or undesired effect of drug occurring at normal dose, during normal use*	90 (29.3)
Adverse health outcomes associated with inappropriate drug use	51 (16.6)
Harm resulting from the use of substandard/counterfeit drugs	26 (8.5)
Harm caused by drug overdose	67 (21.8)
All can define ADR	73 (23.8)
Which ADR should be reported?	
All series ADRs	113 (36.8)
ADRs to herbal and non-allopathic drugs	15 (4.9)
ADRs to new drugs	49 (16.0)
ADRs to vaccines drugs	8 (2.6)
Unknown ADRs to old drugs	9 (2.9)
All of the above*	113 (36.8)
The correct classification of the type of ADR	
Type A,B,C,D,E,and F*	60 (19.5)
Type 1,2,3,4,5,6 and 7	62 (20.2)
Known, unknown and common, uncommon	89 (29.0)
Reversible and irreversible	64 (20.8)
Do not know	31 (10.1)
Is there any center /ADR reporting system in Ethiopia	
Yes	121 (39.4)
No	141 (45.9)
Don't know	45 (14.7)
All ADRs are known before a medicine is marketed.	

1		
2		
3	Yes	99 (32.2)
4	No*	168 (54.7)
5	Don't know	40 (13.0)
6		
7	Are you aware of any drug that banned due to ADR?	
8	Yes*	98 (31.9)
9	No	176 (57.3)
10	Don't know	33 (10.7)
11		
12	Where are ADRs reported in Ethiopia?	
13	Manufacturers	17 (5.5)
14	Ministry of Health of Ethiopia	68 (22.1)
15	Ethiopian pharmaceutical association	47 (15.3)
16	DTC of respective health facility	49 (16.0)
17	FMHACA*	98 (31.9)
18	Pharmacy dept	28 (9.1)
19		
20	Do you think that ADR is the same with side effects?	
21	Yes	127(41.4)
22	No*	180(58.6)
23		
24	Which of the following is the major risk factor for the occurrence of	
25	maximum ADRs	
26	Arthritis	30 (9.8)
27	Renal failure*	147 (47.9)
28	Visual impairment	24 (7.8)
29	All of these	106 (34.5)
30		
31	Overall knowledge score	
32	Good	128 (41.7)
33	Poor	179 (58.3)

ADR: Adverse drug reaction, DTC: drug and therapeutic committee STG: standard treatment guideline DACA: Drug Administration and Control Authority, FMHACA: Food, Medicine and Healthcare Administration and Control Authority, \*correct answers

## Attitude of health professionals toward ADR reporting

Regarding healthcare professionals' attitudes to ADRs reporting, the majority (67.4%) of respondents agreed that it is necessary to report, while 37.8% agreed that ADRs reporting should be mandatory. Most respondents (51.1%) disagreed with the idea that only prescribed medication should be reported. The median (IQR) of the attitude score of ADRs reporting among HCPs was

20 (17–22). Overall, about 60% of respondents showed a positive attitude towards ADRs reporting (table 3).

Table 3: Attitude of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Responses		
	Agree, n (%)	Neutral n (%)	Disagree n (%)
ADR reporting is necessary	207 (67.4)	23 (7.5)	77 (25.1)
ADR reporting should be mandatory for all HCPs	116 (37.8)	62 (20.2)	129 (42.0)
ADR reporting increase patient's safety	148 (48.2)	66 (21.5)	93 (30.3)
ADR reporting is important for health care system	135 (44.0)	73 (23.8)	99 (32.2)
There is a need to be sure that ADRs are related to the drug before reporting	194 (63.2)	35 (11.4)	78 (25.4)
Only ADR of prescription drug needs to be reported	82 (26.7)	68 (22.1)	157 (51.1)
One report of ADR makes no differences	103 (33.6)	78 (25.4)	126 (41.0)
The yellow card is difficult to fill up	177 (57.7)	88 (28.7)	42 (13.7)
ADR reporting creates additional workload and it is time consuming	199 (64.8)	78 (25.4)	30 (9.8)
Establishing ADR reporting center in every hospital is important	189 (61.6)	44 (14.3)	74 (24.1)
Overall level of attitude			
Positive	184 (59.9%)		
Negative	123 (40.1%)		

### Practices of health professionals about ADR reporting

Of the 307 health professionals, 74.9% encountered ADR in the last 12 months of their clinical practice, and 29.1% of them recorded in patient cards. Although most health care professionals experienced ADR, only 32.1% reported it (table 4).

Table 4: Practice of healthcare professionals toward ADR reporting in ACSH, Tigray Region, Northern Ethiopia, from January 2019 to March 2019 (n=307)

Items	Category	Frequency (%)
Have you ever encountered patient with ADR in your clinical practice in the last 12 months	Yes	230(74.9)
	No	77 (25.1)
How many patients with ADR have you encountered during the last 12 months?	None	77 (25.1)
	One	13 (4.2)
	Two	58 (18.9)
	Three	61 (19.9)
	Four	52 (16.9)
Have you noted the ADR you encountered on the patient clinical record (n=230)	More than four	46 (15.0)
	Yes	67 (29.1)
How often do you give advice to your patients on possible ADRs you prescribed, dispensed or administered	No	163 (70.9)
	Usually	118 (38.4)
	Never	89 (29.0)
	Sometimes	69 (22.5)
If you encountered ADR, have you ever reported the ADR? (n=230)	Always	31 (10.1)
	Yes (good practice)	74 (32.1)
	No (poor practice)	156 (67.9)

### Factors associated with poor ADR reporting practice

A univariable logistic regression analysis was performed to determine the association of each variable with the practice of ADR reporting. In the univariable analysis work experience of the HCPs ( $\geq 10$  years) (unadjusted odds ratios (OR) = 0.31, 95% CI: 0.15- 0.64), negative attitude (unadjusted OR = 2.08, 95% CI: 1.17-3.72), poor knowledge (unadjusted OR= 3.49, 95% CI: 1.95-6.23), lack of training on ADR reporting (unadjusted OR= 7.67, 95% CI: 4.07- 14.46), and nursing profession (unadjusted OR= 2.11, 95% CI: 1.06- 4.20), were associated with poor ADR reporting

practice. A subsequent multivariable logistic regression model was conducted to identify the independent predictors. The full model containing all predictors was statistically significant ( $X^2 = 69.78$ ,  $df = 10$ ,  $P$ -value  $< 0.001$ ). The results of the multivariate logistic regression indicated that only work experience of the HCPs ( $\geq 10$  years) (adjusted odds ratios (AOR)= 0.36, 95% CI: 0.13-0.97), poor knowledge (AOR= 2.63, 95% CI: 1.26- 5.45), and lack of training on ADR reporting (AOR= 7.31, 95% CI: 3.42- 15.62) were the predictors of poor ADR reporting practice (table 5).

Table 5: Univariable and multivariable logistic regression analysis of associated factors of poor ADR reporting practice in Tigray Region, Ethiopia from January 2019 to March 2019 (n=230)

Variable	ADR reporting practice		P value	Unadjusted OR (95% CI)	AOR (95% CI)	P value
	good, n (%)	poor, n (%)				
<b>Gender</b>						
Male	44 (59.5)	73 (46.8)		1	1	
Female	30 (40.5)	83 (53.2)	0.07	1.67(0.95, 2.92)	1.51(0.77, 2.94)	0.23
<b>Age (years)</b>						
<25	15(20.3)	29(18.6)		1		
25-34	48(64.9)	100(64.1)	0.84	1.09(0.53, 2.19)	1.22(0.46, 3.23)	0.68
$\geq 35$	11(14.9)	27(17.3)	0.12	1.27(0.49, 3.24)	3.40(0.93, 12.48)	0.07
<b>Experience (years)</b>						
< 5	27(36.5)	84(53.8)		1	1	
5-9	24(32.4)	50(32.1)	0.23	0.67(0.35, 1.28)	1.42(0.57, 3.52)	0.45
$\geq 10$	23(31.1)	22(14.1)	0.001	0.31(0.15, 0.64)	0.36(0.13, 0.97)	0.04
<b>Profession</b>						
Pharmacist	20(27.0)	26(16.7)		1	1	
Physician	16(21.6)	26(16.7)	0.61	1.25(0.53, 2.93)	2.15(0.70, 6.56)	0.18
Nurse	38(51.4)	104(66.7)	0.04	2.11(1.06, 4.20)	1.36(0.57, 3.26)	0.49
<b>Attitude</b>						
Positive	50(67.6)	78(50)		1	1	

Negative	24(32.4)	78(50)	0.01	2.08 (1.17, 3.72)	1.24(0.59, 2.59)	0.57
<b>Knowledge</b>						
Good	48(64.9)	54(34.6)		1	1	
Poor	26(35.1)	102 (65.4)	<0.001	3.49(1.95, 6.23)	2.63(1.26, 5.45)	0.01
<b>Training provided</b>						
Yes	56(75.7)	45(28.8)		1	1	
No	18(24.3)	111(71.2)	<0.001	7.67(4.07, 14.46)	7.31(3.42, 15.62)	<0.001

ADR: adverse drug reaction, AOR: adjusted odds ratio, Unadjusted OR: unadjusted odds ratio

## Discussion

One of the main goals of this study was to investigate the knowledge of HCPs towards ADRs reporting. This issue is critical for research to identify the necessary interventions, as HCPs cannot effectively participate in the reporting without sufficient knowledge of the ADR and its reporting process. We found that only 41.7 % of HCPs had good knowledge about ADR reporting, similar to the reports seen in Amhara region of Ethiopia (47%) [21]. Lack of training on ADRs reporting was significantly associated with insufficient knowledge of ADRs reporting in a study conducted in the Amhara region ( $p = 0.037$ ) [21]. Similarly, in our study, more than half of the participants were untrained, which can lead to insufficient knowledge of the ADRs reporting. This represents an important issue that needs to be addressed, the pharmacovigilance center in Ethiopia should provide training for health care professionals. Our study showed that 39.4% of HCPs were aware of the existence of an ADR system in Ethiopia. This meant that most of the participants did not have information about the authority responsible for monitoring ADRs in Ethiopia. Similarly, lack of knowledge about the national ADR reporting system were reported in different regions of Ethiopia, including a study in Nekemte town which reported that only 30.8% of the HCPs knew the responsible body for ADRs reporting and in Amhara region that reported 49% of the HCPs



1  
2  
3 knew the national ADR reporting system [21, 22]. This is a critical observation, which is  
4 undoubtedly related to the current underreporting of ADRs.  
5  
6

7  
8 Regarding the level of attitude, we found that about 60 % of HCPs had a positive attitude on ADR  
9 and its reporting. Although the majority of the respondents had positive attitude, the result is lower  
10 compared to previous findings in Amhara region of Ethiopia (86%) by Seid et al [21]. This  
11 difference could be due to differences in the measure of attitude in the two studies. In the study by  
12 Seid et al., an arbitrary cut-off value greater than 75% was used to classify participants with a  
13 positive or negative attitude while using the median value in our study. Most respondents (67.4%)  
14 felt that adverse reactions reporting is necessary, which is consistent with previous studies [20,  
15 21]. However, 64.8% of the respondents agreed that reporting creates an additional workload,  
16 which is higher than the results obtained in the Amhara region (32.4%) [21]. Although it may take  
17 some time to complete the report forms, the high proportion of respondents with such perception  
18 found in our study may affect the motivation to report adverse reactions. Healthcare professionals  
19 should consider ADRs reporting as an obligation and should be aware of the existing  
20 pharmacovigilance systems.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 Another important finding was that ADRs reporting practices among HCPs were very poor.  
40 Although more than 75% of respondents encountered one or more ADRs in their daily practice,  
41 only 32.1% of respondents reported ADRs. This is consistent with a study conducted in west  
42 Ethiopia which found only 38.8 % of the participants reported ADRs [22]. Many factors were  
43 mentioned as a reasons for under reporting of ADRs. A study in eastern Ethiopia found that  
44 unavailability of reporting form (53.9%), uncertainty of how to report (51.9%), and lack of  
45 feedback from the responsible body (41%) were the reasons for under reporting [20]. Similarly,  
46 lack of awareness and knowledge on what, when, and to whom to report ADRs (30.8%) and lack  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 of commitments from HCPs(25.5%) were the reason for under reporting of ADRs in a study in  
4 West Ethiopia [22].  
5  
6  
7  
8  
9

10 The study also identified the predictors of poor ADR reporting practices. Less experienced HCPs  
11 were more likely to have poor ADR reporting practices. This finding is consistent with a study  
12 conducted in Uganda, where more experienced HCPs were four times more likely to have ever  
13 reported than less experienced professionals [23]. Health professionals with poor knowledge were  
14 more likely to have a poor practice of ADRs reporting. The association of poor knowledge levels  
15 of health professionals with poor ADR reporting practice has been observed in many similar  
16 previous studies [23-27]. Moreover, health professionals who had not received ADRs reporting  
17 training were more likely to have poor practice. This is also supported by a study carried out in  
18 Spain [28]. However, only 44.95% of the respondents were trained in our study. Similarly, HCPs  
19 have shown limited training in areas of ADR and their reporting in studies conducted in Sudan  
20 [25] and Uganda [23]. Thus, more training regarding the identification of ADR, the purpose of the  
21 ADR reporting, and the availability of resources for ADR reporting is required.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 These findings have important implications. The low level of knowledge of the ADR and its  
41 reporting among HCPs should be enhanced by designing different strategies. A systematic review  
42 of strategies to improve ADRs reporting has shown that multiple interventions appear to have had  
43 more impact than single interventions [13]. Several studies have shown improved knowledge and  
44 attitude scores after educational interventions, including oral workshops, oral presentations, group  
45 discussions, designing ADR newsletters in hospitals, and ongoing training in pharmacovigilance  
46 and ADR reporting [29-33]. Other studies have shown that ADRs reporting has been improved by  
47 offering incentives to health professionals [34, 35]. A study conducted in Spanish that involves  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 both economic incentives and educational activities, resulted in up to a six-fold increase in the  
4 average ADR reporting [36]. Increasing the availability of yellow cards on wards as well as  
5 encouragement to use web-based reporting had improved reporting rates [37]. Therefore,  
6 empowering HCPs in detecting and reporting suspected drug reactions and using strategies that  
7 are evidence-based is essential to strengthening pharmacovigilance systems in Ethiopia. This is  
8 especially important for less experienced health professionals and for those who had never  
9 received training on ADR reporting. However, additional research needs to be done to investigate  
10 the impact of these interventions on the knowledge and practice of ADR reporting in our setting.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Finally, there are several limitations to this study. We used a self-report as the main method of  
25 inquiry, which may have introduced recall bias. The HCPs may have made explicit responses to  
26 the fear that they would be embarrassed if they did not report ADRs. However, because we used  
27 self-administered questionnaires without respondents' names, the potential for this bias was  
28 reduced. The cross-sectional design we used may not establish a causal relationship between ADR  
29 reporting and explanatory variables. Finally, the study was conducted in a tertiary referral hospital  
30 and may not be generalized for all HCPs in different health care levels in the country. Despite  
31 these limitations, our study has generated important insights on knowledge, attitude, and practice  
32 of ADR reporting and predictors of poor ADRs reporting practice.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **Conclusion**

46  
47 **The majority of health professionals had poor knowledge and practice, but a positive attitude**  
48 **toward ADRs reporting.** Poor knowledge, less work experience and lack of training were  
49 predictors of poor ADR reporting practice. Therefore, strategies to improve knowledge and  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 practices regarding ADR reporting should be implemented. Training should be provided to all  
4  
5 HCPs, especially those who have never received training and less experienced professionals.  
6  
7

## 8 9 **Acknowledgments**

10  
11 The authors would like to thank College of Health Science, Mekelle University for their support  
12  
13 and cooperation. The authors would also like to thank for all Ayder comprehensive specialized  
14  
15 hospital staff members for their willingness to participate and dedicate their valuable time to fill  
16  
17 the questionnaire  
18  
19

20  
21  
22 **Contributors:** KG and MS conceived the study and drafted the manuscript and contributed to  
23  
24 data entry, data analysis, draft manuscript and final proof reading. BYH, SWA and YLN  
25  
26 participated in study design, data analysis and in the process of manuscript writing. All authors  
27  
28 approved the final manuscript.  
29  
30

## 31 32 **Data Availability**

33  
34  
35 The dataset of this study is available from the corresponding author upon request.  
36  
37

## 38 39 **Funding statement**

40  
41 This research received no specific grant from any funding agency in the public, commercial or  
42  
43 not-for-profit sectors  
44

## 45 46 **Competing interest**

47  
48 None declared  
49

## 50 51 **Patient consent for publication**

52  
53 Not required  
54

## 55 56 **References**

- 1  
2  
3 1. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions  
4 in Europe: a review of recent observational studies. *Drug safety*. 2015;38(5):437-53. Epub  
5 2015/03/31. doi: 10.1007/s40264-015-0281-0. PubMed PMID: 25822400; PubMed Central  
6 PMCID: PMC4412588.  
7  
8
- 9  
10 2. Campbell JE, Gossell-Williams M, Lee MG. A Review of Pharmacovigilance. *West*  
11 *Indian Med J*. 2014;63(7):771-4. Epub 03/05. doi: 10.7727/wimj.2013.251. PubMed PMID:  
12 25867582.  
13  
14
- 15 3. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-Drug-Reaction-Related  
16 Hospitalisations in Developed and Developing Countries: A Review of Prevalence and  
17 Contributing Factors. *Drug safety*. 2016;39(9):847-57. Epub 2016/07/28. doi: 10.1007/s40264-  
18 016-0444-7. PubMed PMID: 27449638.  
19  
20
- 21 4. Organization WH. Safety of medicines: a guide to detecting and reporting adverse drug  
22 reactions: why health professionals need to take action. Geneva: World Health Organization,  
23 2002.  
24  
25
- 26 5. Huang Y-L, Moon J, Segal JB. A comparison of active adverse event surveillance  
27 systems worldwide. *Drug safety*. 2014;37(8):581-96. Epub 07/15. doi: 10.1007/s40264-014-  
28 0194-3. PubMed PMID: 25022829.  
29  
30
- 31 6. Sabblah GT, Akweongo P, Darko D, Dodoo ANO, Sulley AM. Adverse drug reaction  
32 reporting by doctors in a developing country: a case study from Ghana. *Ghana Med J*.  
33 2014;48(4):189-93. PubMed PMID: 25709133.  
34  
35
- 36 7. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review.  
37 *Drug safety*. 2006;29(5):385-96. Epub 2006/05/13. doi: 10.2165/00002018-200629050-00003.  
38 PubMed PMID: 16689555.  
39  
40
- 41 8. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of  
42 adverse drug reactions: a systematic review. *Drug safety*. 2009;32(1):19-31. Epub 2009/01/10.  
43 doi: 10.2165/00002018-200932010-00002. PubMed PMID: 19132802.  
44  
45
- 46 9. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal  
47 products because of adverse drug reactions: a systematic review of the world literature. *BMC*  
48 *medicine*. 2016;14:10. Epub 2016/02/05. doi: 10.1186/s12916-016-0553-2. PubMed PMID:  
49 26843061; PubMed Central PMCID: PMC4740994.  
50  
51  
52  
53  
54  
55  
56  
57

10. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. *Therapeutics and clinical risk management*. 2005;1(3):181.
11. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. *British journal of clinical pharmacology*. 2017;83(4):875-83. Epub 2016/11/22. doi: 10.1111/bcp.13159. PubMed PMID: 27868226; PubMed Central PMCID: PMC5346870.
12. Perez Garcia M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. *Pharmacoepidemiology and drug safety*. 2011;20(12):1295-302. Epub 2011/07/28. doi: 10.1002/pds.2193. PubMed PMID: 21793098.
13. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. *Drug safety*. 2013;36(5):317-28. Epub 2013/05/04. doi: 10.1007/s40264-013-0058-2. PubMed PMID: 23640659.
14. Alshammari TM, Alamri KK, Ghawa YA, Alohal NF, Abualkol SA, Aljadhey HS. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. *International journal of clinical pharmacy*. 2015;37(6):1104-10. Epub 2015/07/29. doi: 10.1007/s11096-015-0165-5. PubMed PMID: 26216270.
15. Alshami MAAAM, Azm MIMIM. The need of pharmacovigilance activities in Yemen. *Global Journal of Medical Research*. 2014.
16. Mulatu WN, Worku A. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. *Journal of Pharmacovigilance*. 2014.
17. Necho Mulatu W. Assessment of Knowledge, Attitude and Practice of Health Professionals towards Adverse Drug Reaction Reporting and Factors Associated with Reporting 2014.
18. Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society*. 2018;26(4):453-61. Epub 2018/05/31. doi: 10.1016/j.jsps.2018.02.014. PubMed PMID: 29844715; PubMed Central PMCID: PMC5961757.

19. Guner MD, Ekmekci PE. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. *Journal of drug assessment*. 2019;8(1):13-20. Epub 2019/02/08. doi: 10.1080/21556660.2019.1566137. PubMed PMID: 30729064; PubMed Central PMCID: PMC6352929.
20. Shanko H, Abdela J. Knowledge, Attitudes, and Practices of Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study. *Hospital pharmacy*. 2018;53(3):177-87. Epub 2018/08/28. doi: 10.1177/0018578717737430. PubMed PMID: 30147138; PubMed Central PMCID: PMC6102784.
21. Seid MA, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals' knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. *International journal of clinical pharmacy*. 2018;40(4):895-902. Epub 2018/08/11. doi: 10.1007/s11096-018-0682-0. PubMed PMID: 30094559.
22. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. *BioMed research international*. 2016;2016.
23. Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. *Afr Health Sci*. 2015;15(4):1308-17.
24. Ohaju-Obodo J, Iribhogbe O. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. *Pharmacoepidemiology and drug safety*. 2010;19(2):191-5.
25. Elnour AA, Ahmed AD, Yousif MAE, Shehab A. Awareness and reporting of adverse drug reactions among health care professionals in Sudan. *The Joint Commission Journal on Quality and Patient Safety*. 2009;35(6):324-AP2.
26. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. *Drug safety*. 2006;29(5):385-96.
27. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. *British journal of clinical pharmacology*. 2001;51(1):81-6.

- 1  
2  
3 28. Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernandez-Diaz S, Lasheras B. Factors  
4 that influence under-reporting of suspected adverse drug reactions among community  
5 pharmacists in a Spanish region. *Drug safety*. 2007;30(11):1073-82.  
6  
7 29. Jha N, Rathore DS, Shankar PR, Bhandary S, Pandit RB, Gyawali S, et al. Effect of an  
8 educational intervention on knowledge and attitude regarding pharmacovigilance and consumer  
9 pharmacovigilance among community pharmacists in Lalitpur district, Nepal. *BMC research  
10 notes*. 2017;10(1):4.  
11  
12 30. Bisht M, Singh S, Dhasmana D. Effect of educational intervention on adverse drug  
13 reporting by physicians: a cross-sectional study. *ISRN pharmacology*. 2014;2014.  
14  
15 31. Li Q, Zhang S-M, Chen H-T, Fang S-p, Yu X, Liu D, et al. Awareness and attitudes of  
16 healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. *Chinese  
17 medical journal*. 2004;117(6):856-61.  
18  
19 32. Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge  
20 attitude practice of pharmacovigilance among health care professionals in an Indian tertiary care  
21 teaching hospital. *Int J Pharm Tech Res*. 2011;3(2):678-92.  
22  
23 33. Khalili H, Mohebbi N, Hendoiee N, Keshtkar A-A, Dashti-Khavidaki S. Improvement of  
24 knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical  
25 pharmacists' interventional study. *BMJ open*. 2012;2(1):e000367. doi: 10.1136/bmjopen-2011-  
26 000367.  
27  
28 34. Ali S, Egunsola O, Al-Dossari DS, Al-Zaagi IA. Adverse drug reaction reporting in a  
29 large tertiary hospital in Saudi Arabia: results of an incentive strategy. *Therapeutic advances in  
30 drug safety*. 2018;9(10):585-90. Epub 2018/10/05. doi: 10.1177/2042098618790209. PubMed  
31 PMID: 30283626; PubMed Central PMCID: PMC6166318.  
32  
33 35. Chang F, Xi Y, Zhao J, Zhang X, Lu Y. A time series analysis of the effects of financial  
34 incentives and mandatory clinical applications as interventions to improve spontaneous adverse  
35 drug reaction reporting by hospital medical staff in China. *Journal of evaluation in clinical  
36 practice*. 2017;23(6):1316-21. Epub 2017/07/05. doi: 10.1111/jep.12780. PubMed PMID:  
37 28675578.  
38  
39 36. Pedros C, Vallano A, Cereza G, Mendoza-Aran G, Agusti A, Aguilera C, et al. An  
40 intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 time series analysis in Spain. Drug safety. 2009;32(1):77-83. Epub 2009/01/10. doi:  
4 10.2165/00002018-200932010-00007. PubMed PMID: 19132807.  
5

6 37. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: Systematic  
7 review. Clin Epidemiol. 2009;1:75-92. PubMed PMID: 20865089.  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	4 and 5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	--
		(c) Explain how missing data were addressed	--
		(d) If applicable, describe analytical methods taking account of sampling strategy	--
		(e) Describe any sensitivity analyses	--
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	---
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	--
Outcome data	15*	Report numbers of outcome events or summary measures	7-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	12
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	---
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	---
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13 and 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).